# Chapter 30: Premenstrual Dysphoric Disorder

## The Biological and Neurological Basis of Premenstrual Dysphoric Disorder

## Introduction

Premenstrual Dysphoric Disorder (PMDD) is a severe, cyclically recurring mood disorder characterized by a constellation of debilitating emotional, behavioral, and physical symptoms that arise during the late luteal phase of the menstrual cycle and remit shortly after the onset of menstruation (Wakil et al., 2012; Fisher, 2022). Classified within the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) as a distinct depressive disorder, PMDD represents the most severe form of premenstrual symptomatology, affecting an estimated 3% to 9% of women of reproductive age (Bains et al., 2021; Wakil et al., 2012). The disorder is distinguished from the milder and more common Premenstrual Syndrome (PMS) by the predominance and severity of mood symptoms, which cause significant distress and functional impairment in social, occupational, and interpersonal domains (Korzekwa & Steiner, 1997; Pearlstein, 2004; Steiner et al., 2006).

The core diagnostic feature of PMDD is its predictable, cyclical nature, or distinct "on-offness," where symptoms are absent in the week post-menses (the follicular phase) and emerge consistently in the one to two weeks preceding menses (the luteal phase) (Steiner et al., 2006; Korzekwa & Steiner, 1997). The primary symptoms include marked affective lability, persistent and marked anger or irritability, marked anxiety or tension, and a markedly depressed mood, often accompanied by feelings of hopelessness (Wakil et al., 2012; Pearlstein, 2004). These are complemented by behavioral and cognitive symptoms such as decreased interest in usual activities (anhedonia), difficulty concentrating, lethargy or fatigue, and changes in appetite or sleep patterns, including hypersomnia or insomnia (Wakil et al., 2012; Paredes et al., 2019). Physical symptoms, including breast tenderness, headache, bloating, and joint or muscle pain, are also common (Schildkrout, 2014; Abay & Kaplan, 2019; Isgin & Büyüktuncer, 2017). The diagnosis requires prospective daily symptom charting for at least two consecutive menstrual cycles to confirm the timing of symptoms and the degree of impairment, and to differentiate PMDD from a premenstrual magnification (PMM) of an underlying psychiatric disorder (Pearlstein, 2004; Rapkin & Mikacich, 2007; Korzekwa & Steiner, 1997).

For decades, the etiology of severe premenstrual disorders remained an enigma, often dismissed as a normal aspect of the female experience or a purely psychological reaction (Frank, 1986). However, a growing body of evidence now firmly establishes PMDD as a neurobiological condition. The prevailing scientific consensus is that PMDD is not caused by a hormonal imbalance per se, but rather by an abnormal or heightened central nervous system sensitivity to the normal cyclical fluctuations of ovarian steroid hormones, particularly estrogen and progesterone (Cunningham et al., 2009; Subashini et al., 2021; Chavarría Solís, 2013). This abnormal response is believed to be mediated by underlying dysregulation in key neurotransmitter systems and neuroendocrine pathways, unmasking a pre-existing vulnerability in susceptible individuals (Pearlstein, 2006; Halbreich, 1997).

This chapter will provide a comprehensive review of the biological and neurological basis of PMDD, synthesizing evidence from the available literature. It will explore the intricate interplay between neuroendocrine systems, neurotransmitter pathways, and other biological factors that contribute to the pathophysiology of this disorder. By examining the mechanisms implicated in symptom expression, this chapter aims to elucidate the neurobiological foundations of PMDD, providing a basis for understanding its clinical presentation and the rationale behind current and emerging treatment strategies.

## Neurobiological Systems

The pathophysiology of PMDD is complex and multifactorial, with current evidence pointing towards a primary dysregulation of central nervous system (CNS) responses to normal ovarian hormone cycling (Schildkrout, 2014; Cunningham et al., 2009). This section will detail the key neurobiological systems implicated in the disorder, including neurotransmitter pathways and the neuroendocrine axis, which collectively mediate the affective, cognitive, and somatic symptoms characteristic of PMDD.

### Neurotransmitter Systems and Neuropharmacology

A substantial body of evidence implicates several key neurotransmitter systems in the etiology of PMDD, with the serotonergic system being the most extensively studied and understood (Eriksson, 1999; Luecha, 1998). The efficacy of specific psychotropic agents provides strong inferential evidence for the involvement of these systems in the disorder's pathophysiology (Rapkin & Mikacich, 2007).

**The Serotonergic System (5-HT)**
The serotonergic system is critically involved in the regulation of mood, anxiety, aggression, appetite, and sleep—domains that are significantly disrupted in PMDD (Eriksson, 1999; Kennedy, 2008). The most compelling evidence for serotonergic dysregulation in PMDD comes from the well-established efficacy of selective serotonin reuptake inhibitors (SSRIs) as a first-line treatment (Steiner et al., 2006; Pearlstein, 2012). Drugs such as fluoxetine, sertraline, paroxetine, and citalopram have been shown to be highly effective in reducing the mood and behavioral symptoms of PMDD (Eriksson, 1999; Steiner et al., 2006). The therapeutic action of these agents, which increase synaptic serotonin availability, strongly suggests that a functional deficiency or dysregulation in this system is a core component of the disorder (Luecha, 1998; Rapkin & Mikacich, 2007).

Interestingly, the onset of therapeutic action of SSRIs in PMDD is much shorter than in major depressive disorder, with symptom relief often occurring within days of starting treatment rather than weeks (Eriksson, 1999). This rapid response supports the hypothesis that SSRIs in PMDD may not be acting through the slow, adaptive changes in receptor density seen in depression, but rather through a more immediate modulatory effect, possibly on the synthesis of neuroactive steroids (Pearlstein, 2006). Furthermore, SSRIs have been shown to be effective when administered intermittently during the luteal phase only, a dosing strategy that is not typically effective for major depression (Pearlstein, 2012; Eriksson, 1999). This again points to a distinct underlying pathophysiology.

Research suggests that serotonin may play a key role in dampening irritability and anger, which are cardinal symptoms of PMDD (Eriksson, 1999). Studies have identified abnormal serotonergic parameters in women with PMDD not only during the symptomatic luteal phase but also during the asymptomatic follicular phase, suggesting a trait-like vulnerability in this system (Pearlstein, 2006; Halbreich, 1997). This underlying dysregulation is thought to be unmasked by the cyclical hormonal changes, leading to the expression of symptoms. The link between serotonin and appetite is also relevant, as carbohydrate craving is a common PMDD symptom (Wakil et al., 2012; Dilsaver & Coffman, 1988). Serotonergic function is known to be involved in appetite regulation, and compounds that enhance serotonin are more likely to promote weight loss or neutrality, whereas those that antagonize serotonin receptors can stimulate carbohydrate hunger and weight gain (Bernstein, 1988).

**The GABAergic System**
The γ-aminobutyric acid (GABA) system, the primary inhibitory neurotransmitter system in the CNS, is also strongly implicated in PMDD (Alba & Rodríguez, 2014). GABA is crucial for regulating anxiety, tension, and neuronal excitability. The link between the GABA system and PMDD is primarily through the actions of allopregnanolone, a neurosteroid metabolite of progesterone (Pearlstein, 2006). Allopregnanolone is a potent positive allosteric modulator of the GABA-A receptor, acting similarly to benzodiazepines and alcohol to enhance inhibitory neurotransmission (Maj, 2015).

Progesterone levels, and consequently allopregnanolone levels, rise after ovulation and fall just before menstruation, mirroring the timing of PMDD symptoms. It has been hypothesized that women with PMDD have an abnormal or paradoxical response to the normal luteal phase fluctuations in allopregnanolone levels (Pearlstein, 2006). While in most women, allopregnanolone has anxiolytic and calming effects, in women with PMDD it may paradoxically induce anxiety, irritability, and dysphoria. This suggests a dysfunction in the GABA-A receptor complex or its downstream signaling in susceptible individuals (Pearlstein, 2006). The clinical observation that anxiolytics such as benzodiazepines, which also target the GABA-A receptor, can provide some relief for the anxiety and tension in PMS further supports the involvement of the GABAergic system (Riven, 1983).

**The Dopaminergic and Noradrenergic Systems**
Evidence for the involvement of dopamine and norepinephrine in PMDD is less direct than for serotonin and GABA but warrants consideration. These catecholamines are central to motivation, energy, concentration, and mood (Briley, 2011). Symptoms such as lethargy, fatigue, anhedonia (loss of interest or pleasure), and difficulty concentrating are core features of PMDD and are also associated with catecholamine dysfunction (Wakil et al., 2012; Kennedy, 2008).

Some treatments for PMS have been proposed to act via these systems. For example, Vitamin B6 (pyridoxine) and evening primrose oil have been suggested to help regulate dopamine metabolism (Massil & Brien, 1987). Furthermore, serotonin/norepinephrine reuptake inhibitors (SNRIs) are listed as a pharmacological option for PMDD, suggesting that norepinephrine modulation may contribute to therapeutic effects (Rapkin & Mikacich, 2007). The neuroendocrine changes associated with menopause, which involve fluctuations in estrogen that modulate norepinephrine, are also associated with mood disturbances, providing a parallel model for hormonal influence on this neurotransmitter system (Utian, 2005). Finally, a link between progesterone, estrogen, and the regulation of dopamine has also been proposed (Abubakar, 2021).

### Neuroendocrine and Hormonal Systems

The central hypothesis of PMDD posits that symptoms are not caused by abnormal levels of ovarian hormones but by a centrally-mediated abnormal response to normal hormonal changes (Cunningham et al., 2009). The entire symptom complex is inextricably linked to the cyclical activity of the hypothalamic-pituitary-ovarian (HPO) axis (Kovács et al., 2022).

**Estrogen and Progesterone**
The cyclical fluctuation of estrogen and progesterone is the primary trigger for PMDD symptoms (Schildkrout, 2014; Clayton, 2008). This is most definitively demonstrated by the fact that treatments that suppress ovulation and eliminate these fluctuations—such as gonadotropin-releasing hormone (GnRH) agonists or certain oral contraceptives—are highly effective at eliminating PMDD symptoms (Rapkin & Mikacich, 2007; Kovács et al., 2022). When hormonal cycling is restored, symptoms return, confirming their dependence on the hormonal milieu of the luteal phase (Pearlstein, 2006).

Historically, theories of estrogen/progesterone imbalance, such as "estrogen excess" or "progesterone deficiency," were proposed as direct causes of PMS (Frank, 1986; Frable, 1962). However, numerous studies have failed to find consistent differences in the absolute levels of these hormones between women with and without PMDD (Breckwoldt & Zahradnik, 1989). Instead, the focus has shifted to the *downstream effects* of these hormonal changes on CNS function in vulnerable individuals (Schildkrout, 2014). Estrogen and progesterone receptors are widely distributed throughout the brain, particularly in limbic areas that regulate mood and emotion. These hormones have profound effects on the synthesis, release, and metabolism of neurotransmitters, including serotonin, dopamine, and GABA, and they modulate the expression of their receptors (Duval et al., 2010; Abubakar, 2021). Thus, the normal rise and fall of these hormones during the luteal phase can destabilize these neurotransmitter systems in women with an underlying predisposition, leading to the emergence of mood and behavioral symptoms (Rabiepoor & yas, 2018).

**Hypothalamic-Pituitary-Adrenal (HPA) Axis**
The HPA axis is the body's primary stress response system. Research suggests that women with PMDD may exhibit altered HPA axis reactivity (Halbreich, 1997). Stress is known to be a significant trigger or exacerbating factor for PMDD symptoms (Rabiepoor & yas, 2018; Gailliot et al., 2010). Ovarian steroids are known to modulate HPA axis function, and it has been proposed that the hormonal shifts of the luteal phase may lead to a state of HPA axis dysregulation in susceptible women, contributing to symptoms of anxiety, irritability, and fatigue (Halbreich, 1997). Some studies have noted abnormalities in cortisol secretion patterns in women with severe PMS, suggesting a link between the stress system and premenstrual symptomatology (Goodyer et al., 2000).

**Other Hormonal Factors**
Several other endocrine factors have been hypothesized to play a role. Prolactin, involved in breast physiology, was considered a potential contributor to symptoms like breast tenderness (Fernandes et al., 2004), and treatments targeting prolactin, such as bromocriptine, have been used for this specific symptom (Dean et al., 1986). Aldosterone, a hormone involved in fluid and salt balance, has been linked to the somatic symptoms of bloating and fluid retention (Smith & Youngkin, 1986; Dunnigan et al., 1999). Additionally, some research has suggested a state of "relative hypothyroidism" in women with PMDD, even when asymptomatic, pointing to a potential trait-like vulnerability in thyroid function (Halbreich, 1997). Finally, melatonin, the key hormone regulating circadian rhythms and sleep, has been implicated in the sleep disturbances of PMDD. Studies suggest that melatonin function may be lower during the luteal phase in women with PMDD, which could directly contribute to both insomnia and hypersomnia (Yamada, 2016).

### Other Implicated Biological Pathways

Beyond direct neurotransmitter and neuroendocrine mechanisms, other biological systems are being explored for their potential role in PMDD.

**Inflammatory and Immune Pathways**
Emerging theories suggest that an inappropriate inflammatory response may contribute to PMDD symptoms (Enkova et al., 2025). Pro-inflammatory cytokines have been shown to induce "sickness behaviors," which overlap significantly with PMDD symptoms, including fatigue, anhedonia, social withdrawal, and altered sleep and appetite (Anisman et al., 2005). Ovarian hormones modulate immune function, and it is plausible that luteal phase hormonal shifts could trigger a pro-inflammatory state in vulnerable women, contributing to both the physical and psychological symptom burden (Anisman & Merali, 2003).

**Metabolic and Bioenergetic Factors**
A novel hypothesis posits that PMS symptoms, particularly those related to impaired self-control (e.g., emotional lability, impulsivity, increased food intake), may stem from a state of limited metabolic energy (Gailliot et al., 2010). According to this model, the significant metabolic demands of the ovaries and reproductive system during the luteal phase divert glucose resources away from the brain, particularly the prefrontal cortex, which is essential for executive functions and self-regulation. This relative energy deficit could impair the brain's ability to control emotions, impulses, and attention, leading directly to many of the hallmark behavioral and cognitive symptoms of the disorder (Gailliot et al., 2010).

## Genetic and Molecular Basis

While environmental and psychological stressors can influence the severity of PMDD, the cyclical and predictable nature of the disorder, coupled with its response to biological interventions, points toward a strong underlying biological and genetic predisposition. The search for the molecular underpinnings of PMDD focuses on identifying the heritable factors that create a state of vulnerability to ovarian hormone fluctuations.

### Heritability and Genetic Factors

Although the specific genes responsible for PMDD have not been definitively identified in the literature provided, a genetic contribution is strongly suggested by several lines of indirect evidence. The concept of PMDD as an expression of underlying "vulnerability traits" implies a stable, likely heritable, predisposition (Halbreich, 1997; Halbreich, 1995). These traits are thought to be present throughout the menstrual cycle, not just during the symptomatic luteal phase (Halbreich, 1997). This model aligns with findings that women with PMDD show baseline differences in personality, cognitive function, and certain biological markers compared to women without the disorder, even when asymptomatic (Halbreich, 1997).

Furthermore, PMDD shares significant clinical and biological overlap with other mood and anxiety disorders, such as major depressive disorder (MDD) and panic disorder, which have established heritability (Halbreich, 1995; Roy, 1996). A family history of mood disorders is a recognized risk factor for PMDD, suggesting a shared genetic diathesis (Nanagas, 2011). It is hypothesized that some of the same genetic factors that confer risk for depression or anxiety may also predispose an individual to PMDD, with the menstrual cycle acting as a specific trigger for symptom expression in the latter (Halbreich, 1997). The increased sensitivity to panicogenic challenges, such as lactate infusions and carbon dioxide inhalation, seen in women with PMS is similar to that observed in patients with panic disorder, further supporting a potential shared biological vulnerability (Halbreich, 1995; Halbreich, 1997).

### Molecular Mechanisms

At the molecular level, research has focused on the systems that interact with ovarian steroids. The primary candidates for the site of dysfunction in PMDD are the receptors and signaling pathways for key neurotransmitters and neurosteroids.

**Serotonin Receptors and Transporters:** The serotonergic system is a major focus of molecular research in PMDD. Ovarian steroids are known to modulate multiple aspects of this system, including serotonin synthesis, reuptake, and receptor density. It is theorized that women with PMDD may have an underlying inefficiency or instability in their serotonergic system, which is then destabilized by the hormonal changes of the luteal phase. For instance, some evidence suggests that compounds antagonizing or downregulating serotonin receptors may be more likely to stimulate symptoms like carbohydrate craving and weight gain, which are common in PMDD (Bernstein, 1988). Conversely, the efficacy of SSRIs, which block the serotonin transporter protein, provides strong evidence that this molecular target is central to the disorder's pathophysiology (Steiner et al., 2006).

**GABA-A Receptor Complex:** The GABA-A receptor is another critical molecular site. This receptor complex has a binding site for neurosteroids like allopregnanolone, a metabolite of progesterone. In most individuals, allopregnanolone binding enhances GABAergic inhibition, leading to anxiolytic and sedative effects. However, in women with PMDD, a paradoxical reaction has been proposed, where this neurosteroid fails to produce the expected calming effect or even induces anxiety and irritability (Pearlstein, 2006). This suggests a possible alteration in the subunit composition or function of the GABA-A receptor in susceptible women, making it respond abnormally to the luteal phase surge in allopregnanolone. This molecular-level dysfunction could be a core component of the vulnerability to PMDD.

**Hormone Receptors:** While absolute hormone levels are not consistently different in women with PMDD, it is possible that there are differences in the sensitivity or expression of estrogen and progesterone receptors within key brain regions. These receptors act as transcription factors, and alterations in their function could lead to an exaggerated downstream cascade of neurochemical changes in response to normal hormonal signals. This area, however, requires more specific investigation.

**Other Molecular Pathways:** Other molecular pathways implicated in PMDD include those related to prostaglandin synthesis, which has been linked to both physical and emotional premenstrual symptoms (Frank, 1986; Rabiepoor & yas, 2018). Prostaglandin inhibitors can provide some relief, particularly for physical symptoms like dysmenorrhea, which often co-occurs with PMS (Clayton, 2008). Additionally, the inflammatory cascade, involving pro-inflammatory cytokines like IL-1 and TNF-α, represents another potential molecular pathway, as these molecules can directly influence brain function and produce depressive and fatigue-like symptoms (Enkova et al., 2025; Anisman et al., 2005). Finally, the regulation of melatonin receptors (MT1/MT2) may be involved in the sleep disturbances seen in PMDD, as suggested by lower melatonin function in the luteal phase and the potential efficacy of melatonin agonists (Yamada, 2016).

## Brain Structure and Function

While the provided literature is rich in clinical and neurochemical hypotheses, it notably lacks direct evidence from neuroimaging studies, such as functional magnetic resonance imaging (fMRI) or positron emission tomography (PET), specifically investigating brain structure and function in PMDD. This represents a significant gap in the current understanding and an important avenue for future research. However, by integrating the known symptom profile of PMDD with findings from related psychiatric and neurological disorders, we can infer the likely involvement of specific brain regions and neural circuits.

### Implicated Brain Regions

The symptom constellation of PMDD—affective lability, depression, anxiety, irritability, and cognitive dysfunction—strongly points to the involvement of the limbic system and the prefrontal cortex, which are central to emotional regulation, stress response, and executive function (Dodd, 2007; Kennedy, 2008).

**Limbic System:** This network of structures, including the amygdala, hippocampus, and hypothalamus, is fundamental to the processing of emotions, memory, and autonomic/endocrine control. The amygdala is central to the fear and anxiety response, and its hyperactivity could underlie the marked anxiety, tension, and irritability seen in PMDD (Halbreich, 1995). The hippocampus, critical for memory and regulation of the HPA axis, could be involved in the cognitive symptoms (difficulty concentrating, forgetfulness) and the altered stress response observed in the disorder (Schildkrout, 2014; Goodyer et al., 2000). The hypothalamus, as the command center for the HPO and HPA axes, is axiomatically involved, orchestrating the hormonal fluctuations that trigger PMDD and mediating the neuroendocrine response to stress (Kovács et al., 2022; Schildkrout, 2014).

**Prefrontal Cortex (PFC):** The PFC, particularly the orbitofrontal and dorsolateral regions, is responsible for executive functions, including impulse control, emotional regulation, decision-making, and attention (Wheeler, 2014). The impulsivity, emotional lability, and concentration difficulties characteristic of PMDD suggest PFC dysfunction (Gailliot et al., 2010; Wakil et al., 2012). The PFC exerts top-down regulatory control over limbic structures like the amygdala, and a failure of this inhibition during the luteal phase could lead to the emotional dysregulation that defines PMDD. The metabolic energy hypothesis of PMS specifically implicates the PFC, suggesting that a diversion of glucose resources during the luteal phase impairs its self-regulatory capacity (Gailliot et al., 2010).

**Basal Ganglia:** Some research points to the involvement of cortical-basal ganglia circuits, which are implicated in habit formation, motor control, and repetitive behaviors (RAPOPORT & Fiske, 1998). While more central to obsessive-compulsive disorder (OCD), the presence of repetitive negative thoughts and some compulsive-like behaviors (e.g., food cravings, binge eating) in PMDD could suggest a role for these circuits (Wakil et al., 2012).

### Neural Circuits and Functional Connectivity

Based on the implicated neurotransmitter and neuroendocrine systems, dysfunction within several large-scale neural circuits is hypothesized to underlie PMDD.

**The Serotonin Pathway:** Circuits originating in the raphe nuclei and projecting widely to the cortex, limbic system, and hypothalamus are central to the serotonin hypothesis of PMDD. Dysregulation within this system, triggered by hormonal changes, would be expected to alter functional connectivity between these regions, leading to the observed mood and cognitive symptoms (Eriksson, 1999).

**The Brain-Gut Axis:** The bidirectional communication pathway between the brain and the gastrointestinal (GI) tract is increasingly recognized as a key player in both functional GI disorders and mood disorders (Mayer & Tillisch, 2010; Holtmann et al., 2017). Many of the somatic symptoms of PMDD, such as bloating, appetite changes, and other GI complaints, may be mediated by this axis (Schildkrout, 2014). Stress and emotional state, regulated by the brain, are known to influence gut motility, secretion, and visceral perception (Fukudo et al., 1992). Conversely, signals from the gut can influence mood and behavior. It is plausible that the neuroendocrine and inflammatory shifts of the luteal phase disrupt brain-gut communication, contributing to the physical symptom burden of PMDD.

**The Stress Circuitry:** The network connecting the PFC, amygdala, and hypothalamus forms the core of the brain's stress response system. An abnormal response to ovarian steroids could alter the functional balance within this circuit, leading to a state of heightened stress reactivity, anxiety, and impaired emotional control during the luteal phase (Halbreich, 1997).

While direct neuroimaging evidence is absent in the provided sources, the consistent clinical picture and response to targeted neuropharmacological treatments strongly support the involvement of these brain regions and circuits. Future neuroimaging studies are critical to directly visualize and confirm these functional and structural alterations in women with PMDD, comparing symptomatic luteal phase states to asymptomatic follicular phase states.

## Developmental Neurobiology

The emergence and course of PMDD are intrinsically linked to the developmental stages of a woman's reproductive life, from the onset of ovulatory cycles at puberty to their cessation at menopause. A developmental neurobiological perspective suggests that PMDD is not an event that appears de novo, but rather a condition whose expression is contingent on the interaction between an underlying, stable vulnerability and the changing hormonal environment across the lifespan.

### Onset, Course, and Critical Periods

PMDD symptoms, by definition, are tied to ovulatory menstrual cycles and therefore typically emerge after menarche, often during adolescence or early adulthood (Fisher, 2022). The disorder is characterized by its chronic, cyclical course throughout the reproductive years (Subashini et al., 2021). The severity of symptoms can fluctuate over time and may worsen with age, particularly during the late 30s and 40s, leading up to the menopausal transition (Fiebai et al., 2019).

Several key developmental periods represent windows of vulnerability for the onset or exacerbation of mood disorders in women, driven by significant hormonal shifts. These include puberty, the postpartum period, and the perimenopause (Duval et al., 2010). PMDD can be seen as the prototypical example of this phenomenon, where the "reproductive event" is the monthly menstrual cycle itself. The perimenopause, a period characterized by erratic hormonal fluctuations preceding the final menstrual period, is a particularly high-risk time for an increase in mood lability, depression, and anxiety (Rasgon et al., 2005; Maki et al., 2018). Women with a history of PMDD may be especially vulnerable during this transition. Interestingly, some reports suggest that PMS-like symptoms can continue to occur cyclically even after menopause, hinting that the underlying neural mechanisms may persist even in the absence of ovarian cycling (Unknown, 1965).

### The Vulnerability-Stress Model

The most compelling developmental model for PMDD is a diathesis-stress or vulnerability-stress model (Halbreich, 1997). In this framework, the cyclical hormonal fluctuations of the menstrual cycle act as a recurring biological "stressor." However, this stressor only leads to the clinical syndrome of PMDD in women who possess a pre-existing, trait-like vulnerability. This vulnerability is not transient but is a stable characteristic of the individual's neurobiology (Halbreich, 1997).

Evidence for this model comes from studies showing that women with PMDD exhibit biological and psychological differences from control subjects even during their asymptomatic follicular phase (Halbreich, 1997; Halbreich, 1995). These trait markers may include alterations in serotonergic and GABAergic function, heightened sensitivity of the HPA axis, unique personality profiles, and subtle cognitive differences (Halbreich, 1997; Pearlstein, 2006). Therefore, the onset of PMDD symptoms during the luteal phase is not the emergence of a new pathology but the unmasking or triggering of a latent predisposition by the hormonal milieu (Pearlstein, 2006). This model helps to explain why only a subset of women develops PMDD despite all women experiencing similar cyclical hormonal changes. It also suggests that the biological basis of PMDD may be related to a broader vulnerability for other affective disorders, such as major depression and anxiety disorders (Halbreich, 1995; Roy, 1996). The observation that many women with PMDD have a personal or family history of other mood disorders supports this shared vulnerability hypothesis (Nanagas, 2011).

This developmental perspective shifts the focus from viewing PMDD as simply a hormonal disorder to understanding it as a neurodevelopmental condition where the brain's capacity to adapt to hormonal change is compromised. This has significant implications for both research and treatment, suggesting that interventions might be aimed not only at managing the acute luteal phase symptoms but also at addressing the underlying, persistent vulnerability.

## Treatment Mechanisms

Understanding the biological basis of interventions for PMDD provides confirmatory evidence for the pathophysiological theories of the disorder. The efficacy of treatments that target specific neurotransmitter systems or the neuroendocrine axis reinforces the central role of these systems in the expression of PMDD symptoms.

### Pharmacological Interventions

**Serotonergic Agents (SSRIs/SNRIs):** The success of SSRIs as a first-line therapy for PMDD is the strongest clinical evidence supporting the serotonin dysregulation hypothesis (Steiner et al., 2006; Eriksson, 1999). By blocking the reuptake of serotonin, these agents increase its availability in the synaptic cleft, thereby correcting the proposed functional deficit that is exacerbated during the luteal phase (Rapkin & Mikacich, 2007). The rapid onset of action and the effectiveness of intermittent luteal-phase-only dosing suggest a mechanism distinct from that in major depression (Eriksson, 1999; Pearlstein, 2012). This may involve a rapid modulation of neurosteroid synthesis or receptor sensitivity, rather than slower changes in receptor expression (Pearlstein, 2006). The demonstrated ability of SSRIs to specifically reduce irritability and anger further supports the role of serotonin in regulating these core PMDD symptoms (Eriksson, 1999).

**Hormonal Therapies:** Treatments that suppress ovulation provide definitive proof that the cyclical fluctuations of ovarian hormones are the primary trigger for PMDD symptoms (Cunningham et al., 2009). Gonadotropin-releasing hormone (GnRH) agonists create a state of medical menopause by downregulating the HPO axis, thereby eliminating the cyclical production of estrogen and progesterone (Rapkin & Mikacich, 2007; Kovács et al., 2022). This intervention effectively abolishes PMDD symptoms, which promptly return upon cessation of treatment and resumption of ovulation. Similarly, certain formulations of oral contraceptives, particularly those containing drospirenone and administered in a continuous or extended-cycle fashion, can be effective by suppressing ovulation and stabilizing hormone levels (Pearlstein, 2006; Clayton, 2008). The mechanism of these therapies is straightforward: they remove the cyclical trigger.

**Anxiolytics:** The use of benzodiazepines for symptoms of anxiety and tension provides some support for the involvement of the GABAergic system (Riven, 1983). These drugs act as positive allosteric modulators of the GABA-A receptor, enhancing its inhibitory function. Their ability to alleviate anxiety in PMS suggests that a state of reduced GABAergic tone or abnormal receptor function may contribute to the symptom profile (Facchinetti et al., 1998).

### Non-Pharmacological and Other Interventions

**Lifestyle and Behavioral Changes:** Interventions such as regular aerobic exercise are recommended as part of the initial management of PMS and PMDD (Paredes et al., 2019; Ransom & Moldenhauer, 1998). Exercise is known to have beneficial effects on mood and can modulate several neurotransmitter systems, including serotonin, dopamine, and endorphins, which may help to stabilize CNS function during the luteal phase (Smith & Blumenthal, 2015). Stress reduction techniques and cognitive behavioral therapy (CBT) also show efficacy (Abay & Kaplan, 2019; Pearlstein, 2012). These interventions may work by improving coping mechanisms and reducing the impact of psychosocial stressors, which are known to exacerbate PMDD symptoms, possibly by downregulating the HPA axis response (Rabiepoor & yas, 2018).

**Nutritional and Complementary Approaches:** Certain nutritional supplements have been investigated for PMS. Calcium supplementation has shown some evidence of efficacy, though the mechanism is unclear (Pearlstein, 2012). Vitamin B6 (pyridoxine) has been proposed to influence the synthesis of dopamine and serotonin, which could explain its potential benefit (Massil & Brien, 1987; Dean et al., 1986). The herbal supplement Chasteberry (Vitex agnus-castus) is also used, with some evidence supporting its efficacy, possibly through dopaminergic effects or by influencing prolactin levels (Pearlstein, 2012).

In summary, the mechanisms of the most effective treatments for PMDD—SSRIs and ovulation suppression—converge to support a "two-hit" model of pathophysiology: a primary, underlying CNS vulnerability (likely serotonergic and GABAergic in nature) that is cyclically activated by the normal fluctuations of ovarian steroid hormones.

## Future Directions

While significant progress has been made in establishing PMDD as a distinct neurobiological disorder, many questions regarding its precise mechanisms, heterogeneity, and long-term trajectory remain unanswered. The limitations of the currently available literature highlight several critical areas for future research that are essential for advancing the field and improving clinical care for women suffering from this debilitating condition.

A primary and urgent need is for neuroimaging research. The provided literature contains no studies utilizing techniques like fMRI, PET, or advanced structural MRI to investigate brain function and structure in women with PMDD. Such studies are crucial to move from neurochemical hypotheses to a circuit-level understanding of the disorder. Future research should employ longitudinal designs to compare brain activity and connectivity between the asymptomatic follicular phase and the symptomatic late luteal phase. This would allow for the direct identification of the neural circuits whose function is altered by hormonal fluctuations, potentially confirming the hypothesized roles of the limbic system, prefrontal cortex, and their interplay.

The genetic basis of PMDD is another area ripe for exploration. While a heritable component is strongly suspected based on the vulnerability trait model and comorbidity with other heritable psychiatric disorders (Halbreich, 1997; Nanagas, 2011), the specific genes that confer this risk are unknown. Genome-wide association studies (GWAS) could identify genetic variants related to serotonin or GABA receptor subunits, steroid hormone metabolism, or inflammatory pathways that predispose individuals to an abnormal CNS response to hormonal changes. Identifying these genetic markers would not only solidify the biological basis of PMDD but could also pave the way for predictive testing and more personalized treatment strategies.

Further investigation into the diverse biological systems implicated in PMDD is also warranted. The preliminary suggestions of involvement from the immune system (inflammatory cytokines) and metabolic pathways (bioenergetics) are intriguing and require rigorous investigation (Enkova et al., 2025; Gailliot et al., 2010). Measuring inflammatory markers and assessing brain glucose metabolism across the menstrual cycle in women with and without PMDD could validate these novel hypotheses and potentially open up entirely new avenues for therapeutic intervention.

The clinical and biological heterogeneity of PMDD also requires further study. It has been proposed that women with PMDD may comprise distinct subsets, such as one with predominant depressive symptoms and another with predominant irritability or anxiety (Pearlstein, 2004). Future research should aim to determine if these clinical subtypes correspond to different underlying biological profiles (e.g., primarily serotonergic vs. primarily GABAergic dysfunction). Identifying such biological subtypes could lead to more targeted and effective treatments, moving beyond the current one-size-fits-all approach.

Finally, long-term prospective studies are needed to understand the full life course of PMDD. How does the disorder evolve with age? What is the impact of major life events, such as pregnancy and the postpartum period, on symptom expression (Duval et al., 2010)? How does PMDD transition into the mood disturbances of perimenopause (Rasgon et al., 2005)? Following women with PMDD from adolescence through menopause would provide invaluable information on the natural history of the disorder and its relationship with other hormone-sensitive mood disorders. Such research is essential for developing comprehensive, lifespan-oriented prevention and management strategies.

## Conclusion

Premenstrual Dysphoric Disorder is a severe and impairing mood disorder with a definitive biological basis, intrinsically linked to the female reproductive cycle. The wealth of clinical and pharmacological evidence reviewed in this chapter converges on a central pathogenetic model: PMDD arises from an abnormal central nervous system response to the normal, cyclical fluctuations of ovarian steroid hormones in genetically vulnerable individuals. This model effectively refutes outdated notions of the disorder as a simple hormonal imbalance or a purely psychological phenomenon.

The core of this vulnerability appears to lie within key neurotransmitter systems responsible for mood and emotional regulation, most notably the serotonergic and GABAergic pathways. Women with PMDD seem to possess a trait-like predisposition, characterized by a latent instability in these systems, which is unmasked by the dramatic shifts in estrogen, progesterone, and its neuroactive metabolites like allopregnanolone during the luteal phase (Halbreich, 1997; Pearlstein, 2006). This interaction precipitates the profound affective, cognitive, and somatic symptoms that define the disorder. The remarkable efficacy of treatments that either stabilize the serotonergic system with SSRIs or abolish hormonal cycling via ovulation suppression provides powerful, convergent validation of this neurobiological framework (Steiner et al., 2006; Rapkin & Mikacich, 2007).

While the fundamental principles of PMDD pathophysiology are becoming clearer, significant gaps in our knowledge remain. The precise molecular and genetic factors conferring vulnerability, the specific neural circuits involved, and the potential roles of other systems such as inflammatory and metabolic pathways, are all critical areas for future investigation. Acknowledging PMDD as a legitimate, biologically-based psychiatric illness is paramount for reducing stigma, promoting accurate diagnosis, and encouraging the development of more targeted and effective treatments. Continued research into the intricate neurobiology of this disorder is essential to improve the quality of life for the millions of women affected by its debilitating cyclical symptoms.

## References

1. Abay, H., & Kaplan, S. (2019). Current Approaches in Premenstrual Syndrome Management. Bezmialem Science. https://doi.org/10.14235/bas.galenos.2018.2358
2. Abdo, C. H. N. (2017). Sexualidade e doenças reumáticas. Revista Paulista de Reumatologia. https://doi.org/10.46833/reumatologiasp.2017.16.3.6-12
3. Abubakar, I. A. (2021). Regular Physical Activity during Pregnancy Improves Maternal Depressive Symptoms. Journal of Pharmacy Practice and Community Medicine. https://doi.org/10.5530/jppcm.2021.1.4
4. Agarwal, V., Sitholey, P., & Srivastava, C. (2019). Clinical practice guidelines for the management of dissociative disorders in children and adolescents. Indian Journal of Psychiatry. https://doi.org/10.4103/psychiatry.indianjpsychiatry_493_18
5. Ahemad, M., Ahmad, P. M. F., & Shafaat, M. (2018). Effect of Dalak (Massage) in the Management of Sahar (Insomnia). https://doi.org/10.37591/rrjoush.v5i2.130
6. Ahmadinejad, F. S. S., Tayebi, N., & Khatami, M. (2019). Difference in Gender and Childbirth Costs and Their Association With Postpartum Depression. International Journal of Women s Health and Reproduction Sciences. https://doi.org/10.15296/ijwhr.2021.24
7. Ahmed, S., & Paul, S. P. (2019). A Diagnostic Conundrum: Acute Intermittent Porphyria Coexisting with Lumbar Prolapsed Intervertebral Disc. Journal of College of Physicians And Surgeons Pakistan. https://doi.org/10.29271/jcpsp.2019.12.1236
8. AL-Ibraheem, M. T. (2018). Cognitive Behavioral Therapy for Incest “Case Study”. Journal of Education and Practice.
9. Alalet, R. (2018). Reading Disability: Current Practices for Learning. International Journal of Autism & Related Disabilities. https://doi.org/10.29011/2642-3227.000014
10. Alba, P., & Rodríguez, C. V. (2014). [Premenstrual syndrome and dysphoric premenstrual syndrome].. PubMed.
11. Alberdi-Páramo, Í., & Pelaz-Antolín, A. (2019). Emocionalidad y temperamento en el trastorno por déficit de atención con o sin hiperactividad. Revista de Neurología. https://doi.org/10.33588/rn.6908.2019032
12. Alexandre, S., Misery, L., Dutray, S., Chastaing, M., Consoli, S.-M., Audra, H., Bauer, D., Bertolus, S., Callot, V., Cardinaud, F., Corrin, E., Féton-Danou, N., Malet, R., Touboul, S., & Consoli, S. (2007). Functional Itch Disorder or Psychogenic Pruritus: Suggested Diagnosis Criteria From the French Psychodermatology Group. Acta Dermato Venereologica. https://doi.org/10.2340/00015555-0266
13. Ali, N., Rasheed, A., Tariq, I., Abdullah, F., Sarwar, A., Atta, R., & Qammer, Z. (2018). Adjunct Use of Low Dose Risperidone Verses Adjunct Use of Clonazepam with an SSRI in Treatment of Moderate to Severe Anxiety States; A Comparative Study. National Journal of Health Sciences. https://doi.org/10.21089/njhs.32.0051
14. Allgulander, C., & Baldwin, D. S. (2013). Pharmacotherapy of Generalized Anxiety Disorder. Modern trends in psychiatry. https://doi.org/10.1159/000351955
15. Altonbary, A. (2021). A Mental or Behavioural Post Traumatic Disorder.
16. Alves, D. C. L., Gross, J. D. S., Filho, J. D. L. D. C., Pinto, V. A. F. S., Roberto, G. F., Direito, V. C., Tiezzi, J. T. S., Pereira, E., & Gomes, N. P. (2025). DEPRESSÃO PÓS PARTO: UMA ANÁLISE SOBRE DIAGNÓSTICO E MANEJO ADEQUADO . Revista fisio&terapia.. https://doi.org/10.69849/revistaft/fa10202505101617
17. Ananto, A. S., & Suryati, E. (2019). Ensefalopati Hipertensi pada Anak dengan Glomerulonefritis Akut Pasca Streptokokal.
18. Andrasik, F., Lipchik, G. L., McCrory, D. C., & Wittrock, D. A. (2005). Outcome Measurement in Behavioral Headache Research: Headache Parameters and Psychosocial Outcomes. Headache The Journal of Head and Face Pain. https://doi.org/10.1111/j.1526-4610.2005.05094.x
19. Anisman, H., & Merali, Z. (2003). Cytokines, stress and depressive illness: brain‐immune interactions. Annals of Medicine. https://doi.org/10.1080/07853890310004075
20. Anisman, H., Merali, Z., Poulter, M. O., & Hayley, S. (2005). Cytokines as a Precipitant of Depressive Illness: Animal and Human Studies. Current Pharmaceutical Design. https://doi.org/10.2174/1381612053381701
21. Aretouli, E., Malik, M., Widmann, C., Parker, A. M., Oh, E. S., & Vannorsdall, T. D. (2025). Cognitive and mental health outcomes in long covid. BMJ. https://doi.org/10.1136/bmj-2024-081349
22. Armstrong, L. E., Casa, D. J., Millard‐Stafford, M., Moran, D. S., Pyne, S. W., & Roberts, W. O. (2007). Exertional Heat Illness during Training and Competition. Medicine & Science in Sports & Exercise. https://doi.org/10.1249/mss.0b013e31802fa199
23. Arredondo-Aldana, K., Mera-Posligua, M. J., & Alencastro, J. A. P. (2021). Trastorno Depresivo Persistente y Trastornos de Ansiedad Generalizada Proveniente de un Estrés Post Traumático Crónico: Presentación de un Caso Clínico. Revista Científica Arbitrada en Investigaciones de la Salud GESTAR. https://doi.org/10.46296/gt.v4i8edesp.0027
24. Aveyard, P., & Raw, M. (2012). Improving smoking cessation approaches at the individual level. Tobacco Control. https://doi.org/10.1136/tobaccocontrol-2011-050348
25. Awan, K., & Steinberg, M. H. (2017). Medical Conditions That May Cause Cognitive Impairment and Depression. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199959549.003.0005
26. Ayoob, A., & Janakiram, C. (2021). Let's Focus on Frailty. Journal of Indian Association of Public Health Dentistry. https://doi.org/10.4103/jiaphd.jiaphd_93_21
27. Bains, N., Abdijadid, S., & Miller, J. (2021). Major Depressive Disorder (Nursing).
28. Balachandra, A., & Ruckmani, V. S. (2015). A Study on Emotional Intelligence, Family Environment, Mental Health Problems & Pro-Social Behavior. JOURNAL OF PSYCHOSOCIAL RESEARCH.
29. Baldwin, D. S., Ajel, K., & Garner, M. (2008). Anxiety disorders. Medicine. https://doi.org/10.1016/j.mpmed.2008.05.002
30. Banerjee, S., Bhandari, R. P., & Rosenberg, D. R. (2005). Use of Low-Dose Selective Serotonin Reuptake Inhibitors for Severe, Refractory Choking Phobia in Childhood. Journal of Developmental & Behavioral Pediatrics. https://doi.org/10.1097/00004703-200504000-00008
31. Barbosa, M. O. S., Silva, F. L. C., Castro, J. D. O., Marino, L. D. B., Silva, V. D. S., Pinho, R. C., & Bonfim, Y. C. (2018). PROCESSO DE ENFERMAGEM EM PACIENTE COM ESQUIZOFRENIA HEBEFRÊNICA: UM RELATO DE CASO. 13º Congresso Internacional Rede Unida.
32. Barkin, R. L. (2007). Zolpidem Extended-Release: A Single Insomnia Treatment Option for Sleep Induction and Sleep Maintenance Symptoms. American Journal of Therapeutics. https://doi.org/10.1097/mjt.0b013e31804c7292
33. Barton, S., Karner, C., Salih, F., Baldwin, D. S., & Edwards, S. J. (2014). Clinical effectiveness of interventions for treatment-resistant anxiety in older people: a systematic review. Health Technology Assessment. https://doi.org/10.3310/hta18500
34. Batta, A., & Farid, B. (2011). Addiction in Adolescents ---- A Current Trend.
35. Beghi, E., Carpio, A., Forsgren, L., Hesdorffer, D. C., Malmgren, K., Sander, J. W., Tomson, T., & Hauser, W. A. (2009). Recommendation for a definition of acute symptomatic seizure. Epilepsia. https://doi.org/10.1111/j.1528-1167.2009.02285.x
36. Behrman, S., & Ebmeier, K. P. (2014). Can exercise prevent cognitive decline?. PubMed.
37. Belmaker, R. H. (2007). Treatment of Bipolar Depression. New England Journal of Medicine. https://doi.org/10.1056/nejme078042
38. Beriguistain, A. (2019). La Realidad Virtual como Herramienta Terapéutica en Niños con TDAH. NeuroRehabNews. https://doi.org/10.37382/nrn.octubre.2019.575
39. Bernstein, J. G. (1988). Psychotropic drug induced weight gain: mechanisms and management.. PubMed.
40. Bertodo, T. D. S., Gross, M. S., & Maldaner, E. B. (2018). TRANSTORNOS BIPOLAR E DEPRESSIVO: UMA REVISÃO DOS ASPECTOS CONCEITUAIS.
41. Bezerra, E. D. L., & Zimmermann, M. (2015). DISTÚRBIOS COMPORTAMENTAIS EM CÃES: Ansiedade por Separação.
42. Bitnun, A., & Richardson, S. E. (2015). Childhood Encephalitis in Canada in 2015. Canadian Journal of Infectious Diseases and Medical Microbiology. https://doi.org/10.1155/2015/947602
43. Bjorvatn, B., Jernelöv, S., & Pallesen, S. (2021). Insomnia – A Heterogenic Disorder Often Comorbid With Psychological and Somatic Disorders and Diseases: A Narrative Review With Focus on Diagnostic and Treatment Challenges. Frontiers in Psychology. https://doi.org/10.3389/fpsyg.2021.639198
44. Bjørk, M., & Eberhard‐Gran, M. (2018). Perinatal Depression in Neurological Disease and Disability. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190667351.003.0034
45. Blanco, C., & Bernardi, S. (2014). Gambling Disorder. American Psychiatric Publishing eBooks. https://doi.org/10.1176/appi.books.9781585625048.gg62
46. Blumenthal, J. A., & Lett, H. S. (2005). Depression and Cardiac Risk. Journal of Cardiopulmonary Rehabilitation. https://doi.org/10.1097/00008483-200503000-00005
47. Bond, C., Morgenstern, J., & Milne, W. K. (2022). Hot off the press: <scp>MRI</scp> sensitivity for transient global amnesia. Academic Emergency Medicine. https://doi.org/10.1111/acem.14540
48. Bonnet, M. H., & Arand, D. L. (1998). The Consequences of a Week of Insomnia II: Patients with Insomnia. SLEEP. https://doi.org/10.1093/sleep/21.4.359
49. Boylan, K., & Eppel, A. (2008). The severe mood dysregulation phenotype: case description of a female adolescent.. PubMed.
50. Brashear, A., Sweadner, K. J., Cook, J., Swoboda, K. J., & Ozelius, L. J. (2014). ATP1A3-Related Neurologic Disorders. University of Washington, Seattle eBooks.
51. Breckwoldt, M., & Zahradnik, H. P. (1989). Pramenstrnelles Syndrom nnd Dysmenorrho.
52. Briley, M. (2011). Noradrenergic symptom cluster in depression. Neuropsychiatric Disease and Treatment. https://doi.org/10.2147/ndt.s19611
53. Brock, K. A., Nguyen, B., Liu, N., Watkins, M., & Reutzel, T. J. (2005). The Use of Antidepressants in School-Age Children. The Journal of School Nursing. https://doi.org/10.1177/10598405050210060301
54. Brock, K. A., Nguyen, B., Liu, N., Watkins, M., & Reutzel, T. J. (2005). The Use of Antidepressants in School-Age Children. The Journal of School Nursing. https://doi.org/10.1622/1059-8405(2005)021[0318:tuoais]2.0.co;2
55. Brown, S. L. (2006). Deterioration. Epilepsia. https://doi.org/10.1111/j.1528-1167.2006.00682.x
56. Browne, R. B. (2011). The Belle Browne Pain Scale.
57. Brüne, M. (2015). Obsessive-compulsive and related disorders. Oxford University Press eBooks. https://doi.org/10.1093/med:psych/9780198717942.003.0012
58. BS, A. H., & BA, M. F. (2018). Glossary. https://doi.org/10.1002/9781119449737.gloss
59. Buckley, P., & Foster, A. (2014). Schizophrenia. https://doi.org/10.1007/978-3-7091-0715-7_4
60. Budson, A. E., & O’Connor, M. K. (2021). How to manage emotional problems. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780190098124.003.0008
61. Bueno, B. B., Soares, V. S., & Oliveira, C. F. D. (2014). Patologias associadas à deficiências na síntese do grupo heme. Revista Científica da FHO|Uniararas. https://doi.org/10.55660/revfho.v2i2.101
62. Bytzer, P. (2012). New hope for functional dyspepsia?. Gut. https://doi.org/10.1136/gutjnl-2012-301986
63. Büyüktuncer, Z., & Isgin, K. (2017). Nutritional approach in premenstrual syndrome. Turkish Bulletin of Hygiene and Experimental Biology. https://doi.org/10.5505/turkhijyen.2017.46667
64. Canapathy, M., Kurushev, J., Chitra, F., & Dash, M. (2019). Impact of Sensory Deprivation on Health Outcome. Acta Scientific Paediatrics. https://doi.org/10.31080/aspe.2019.02.0165
65. Capaldini, L. (1998). Fatigue and HIV: interview with Lisa Capaldini, M.D. Interview by John S. James.. PubMed.
66. Carlson, K. J., Eisenstat, S. A., & Ziporyn, T. (1997). The Women’s Concise Guide to Emotional Well-Being. https://doi.org/10.2307/j.ctv1r4xd2h
67. Castello, M., Gutiérrez, A. A., Rodríguez, L. S., Pérez, I. S., Arévalo, A. J., & Sempere, E. P. (2025). Acute confusional state vs psychological and behavioral symptoms of dementia. About a case. European Psychiatry. https://doi.org/10.1192/j.eurpsy.2025.1797
68. Castillo-Villanueva, E., Coy, P. E. C., Shejet, F. O., Durán, E. T., & Cabrera, D. M. (2010). Evaluación de funciones cognitivas: atención y memoria en pacientes con trastorno de pánico. Salud Mental.
69. Chaijan, P. Y., Salehi, B., Khosrobeigi, A., Hajirahimi, M., Rafiei, M., & Ahmadi, H. T. (2014). Prevalence of Obsessive-Compulsive Disorder in Pediatric Patients with the Daytime Frequency Syndrome of Childhood or Pollakiuria. Journal of Arak University of Medical Sciences.
70. Chaouloff, F., Dubreucq, S., Matias, I., & Marsicano, G. (2013). Physical activity feel-good effect:The role of endocannabinoids. Routledge eBooks. https://doi.org/10.4324/9780203132678-12
71. Chua, A. S. B. (2011). Prevalence of Irritable Bowel Syndrome in Northern India. Journal of Neurogastroenterology and Motility. https://doi.org/10.5056/jnm.2011.17.1.6
72. Chuster, A. (2019). Long-lasting hypnagogic states of mind, sub-thalamic fears and caesura. Routledge eBooks. https://doi.org/10.4324/9780429444364-15
73. Cienfuegos, J. J., Arriaga, M. Á. A., García, J. J., & Fernández, A. C. S. (2021). Propuesta de establecimiento de hábitos y rutinas que contemplen ejercicio y manejo del estrés para evitar el desgaste laboral durante el home office. Ciencia Latina Revista Científica Multidisciplinar. https://doi.org/10.37811/cl_rcm.v5i3.583
74. Clauw, D. J. (2010). Perspectives on Fatigue from the Study of Chronic Fatigue Syndrome and Related Conditions. PM&R. https://doi.org/10.1016/j.pmrj.2010.04.010
75. Clayton, A. H. (2008). Symptoms Related to the Menstrual Cycle: Diagnosis, Prevalence, and Treatment. Journal of Psychiatric Practice. https://doi.org/10.1097/01.pra.0000308491.54885.f8
76. Clunie, G., Wilkinson, N., Nikiphorou, E., & Jadon, D. R. (2018). Evaluating rheumatological and musculoskeletal symptoms. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198728252.003.0001
77. Cm, B. (1988). The psychiatric epidemic in the American workplace.. PubMed.
78. Compton, M. T., & Broussard, B. (2010). Psychosocial Treatments for Early Psychosis. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780195372496.003.0016
79. Cooper, L., Copeland, S., Dailey, S., Downey, D., Petersen, M. C., Stimson, C., & Dyke, D. C. V. (2008). Feeding and swallowing dysfunction in genetic syndromes. Developmental Disabilities Research Reviews. https://doi.org/10.1002/ddrr.19
80. Copeland‐Linder, N., Onigu-Otite, E., Serico, J. M., Jamora, M., & Belcher, H. M. E. (2017). Neurobiology of Child Maltreatment and Psychological Trauma. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199937837.003.0181
81. Couto, F. S. D., & Mendonça, A. D. (2010). Sintomas psiquiátricos e comportamentais da demência. Revista Portuguesa de Clínica Geral. https://doi.org/10.32385/rpmgf.v26i1.10713
82. Croci, I., Byrne, N. M., Choquette, S., Hills, A. P., Chachay, V., Clouston, A. D., O'Moore‐Sullivan, T., Macdonald, G. A., Prins, J. B., & Hickman, I. J. (2012). Whole-body substrate metabolism is associated with disease severity in patients with non-alcoholic fatty liver disease. Gut. https://doi.org/10.1136/gutjnl-2012-302789
83. Cunha, M. J., Sousa, A. K. A. D., & Pereira, J. P. (2010). Health and wellbeing in Portuguese Pre-hospital Emergency volunteers: An intervention model based on promotion of personal and organizational resources..
84. Cunningham, J., Yonkers, K. A., O’Brien, S., & Eriksson, E. (2009). Update on Research and Treatment of Premenstrual Dysphoric Disorder. Harvard Review of Psychiatry. https://doi.org/10.1080/10673220902891836
85. Czajkowska‐Malinowska, M., & Cofta, S. (2014). Obturacyjny bezdech senny i jego społeczne następstwa.
86. Daley, D. C., & Douaihy, A. (2019). Substance-Related Disorders. Oxford University Press eBooks. https://doi.org/10.1093/med-psych/9780190926632.003.0002
87. Davis, S., Gupta, N., Samudra, M., & Javadekar, A. (2021). A case of frontal lobe syndrome. Industrial Psychiatry Journal. https://doi.org/10.4103/0972-6748.328859
88. Dean, C., Steinberg, S. K., & Sylvester, W. H. (1986). Medical management of premenstrual syndrome.. PubMed.
89. Dean, G., & Wadia, N. H. (1995). Multiple sclerosis in the Parsis.. Journal of Neurology Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp.58.2.254
90. Deep, D. B. (2021). STRESS AND CONSTIPATION (VIBANDHA) - CRITICAL REVIEW. Ayurline International Journal of Research in Indian Medicine. https://doi.org/10.52482/ayurline.v5i04.569
91. Dejan, S., Jelica, S.-T., & Dusica, D. (2013). Heart rate modulations in overtraining syndrome. Serbian Journal of Experimental and Clinical Research. https://doi.org/10.5937/sjecr14-4388
92. DeLuca, G. C., & Bartleson, J. D. (2010). When and How to Investigate the Patient with Headache. Seminars in Neurology. https://doi.org/10.1055/s-0030-1249221
93. Demb, H. B., Papola, P., Rosenberg, R. L., & Plum, E. (1998). A Typical Children Followed-Up in Adolescence. Clinical Child Psychology and Psychiatry. https://doi.org/10.1177/1359104598032011
94. Dennis, M., Warlow, C. P., Gijn, J. V., Wardlaw, J. M., Bamford, J., Hankey, G. J., Sandercock, P., Rinkel, G. J., Langhorne, P., Sudlow, C., & Rothwell, P. M. (2008). What are This Patient's Problems?: A Problem‐Based Approach to the General Management of Stroke. Stroke. https://doi.org/10.1002/9780470696361.ch11
95. Derman, E., Whitesman, S., Dreyer, M., Patel, D., Nossel, C., & Schwellnus, M. (2010). Healthy lifestyle interventions in general practice: Part 12: Lifestyle and depression. South African Family Practice. https://doi.org/10.1080/20786204.2010.10873989
96. Dias, R. D. S. (2010). Estudo comparativo do fenótipo clínico de mulheres com transtorno afetivo bipolar em fase reprodutiva da vida com e sem piora pré-menstrual do humor. https://doi.org/10.11606/t.5.2010.tde-28052010-101220
97. Dilsaver, S. C., & Coffman, J. A. (1988). Seasonal depression.. PubMed.
98. Dilú, L., & Vázquez, F. (2022). An approach to music therapy and its impact on the management of schizophrenia. Advances in Ophthalmology & Visual System. https://doi.org/10.15406/aovs.2022.12.00421
99. Dobrescu, I., Rad, F., Anghel, G. C., Stancu, M., & Buică, A. (2017). P288 Somatic complaints in anxiety disorders. https://doi.org/10.1136/archdischild-2017-313273.376
100. Dodd, M. L. (2007). BASIC PRINCIPLES OF PSYCHIATRY. CRC Press eBooks. https://doi.org/10.1201/b14430-11
101. Doyle, A., & Pollack, M. H. (2003). Establishment of Remission Criteria for Anxiety Disorders. The Primary Care Companion To The Journal of Clinical Psychiatry.
102. Dragoș, D., Ionescu, O.-P., Micuţ, R., Ojog, D. G., & Tănăsescu, M. D. (2012). Psychoemotional features of a doubtful disorder: functional dyspepsia.. PubMed.
103. Dubovický, M. (2010). Neurobehavioral manifestations of developmental impairment of the brain. Interdisciplinary Toxicology. https://doi.org/10.2478/v10102-010-0012-4
104. Dunnigan, M., Czapla, K., Henderson, J. B., & Pelosi, A. J. (1999). The Fluid Retention Syndrome: Recognition, Risk Factors and Management. The Journal of the British Menopause Society. https://doi.org/10.1177/136218079900500206
105. Dunsky, A. (2019). The Effect of Balance and Coordination Exercises on Quality of Life in Older Adults: A Mini-Review. Frontiers in Aging Neuroscience. https://doi.org/10.3389/fnagi.2019.00318
106. Duval, F., Jautz-Duval, M. M., González, F., & Rabia, H. (2010). Bases neurobiológicas de vulnerabilidad psiquiátrica a lo largo de las etapas de la vida hormonal de la mujer. Revista chilena de neuro-psiquiatría. https://doi.org/10.4067/s0717-92272010000500005
107. Dwigint, S. (2015). THE RELATION OF DIET PATTERN TO DYSPEPSIA SYNDROM IN COLLEGE STUDENTS. Jurnal Majority.
108. Dyson, S., & Thomson, K. (2021). The recognition of pain and learned behaviour in horses which buck. Equine Veterinary Education. https://doi.org/10.1111/eve.13466
109. Dziegielewski, S. F. (2014). Quick References. https://doi.org/10.1002/9781394260577.bapp01
110. Elbert, T., Schauer, M., & Neuner, F. (2004). Memory of Traumatic Stress. Klinische Neurophysiologie. https://doi.org/10.1055/s-2004-831963
111. Enkova, E. V., Khoperskaya, O. V., Enkova, V. V., & Karpova, D. V. (2025). Premenstrual syndrome: A modern view on the problem. Meditsinskiy sovet = Medical Council. https://doi.org/10.21518/ms2024-556
112. Enrique, P. M. L., Gloria, A. S., Efraín, S. C. J., & Luis, G. A. J. (2019). Latencia diagnóstica en la enfermedad de Parkinson y su relación con los síntomas prodrómicos motores y no motores. eNeurobiología.
113. Ensalada, L. H., Brigham, C. R., & Kertay, L. (2018). Somatization. AMA guides newsletter. https://doi.org/10.1001/amaguidesnewsletters.2018.julaug03
114. Eriksson, E. (1999). Serotonin reuptake inhibitors for the treatment of premenstrual dysphoria.. PubMed.
115. Eskander, F. S. L., Hakim, K. Y. K., Ibrahim, D., & ElMallah, W. (2021). Incidence Of Post-Operative Delirium In Geriatric Patients Undergoing Hip Replacement Surgery Using Pre-Operative Haloperidol. QJM. https://doi.org/10.1093/qjmed/hcab086.109
116. Facchinetti, F., Tarabusi, M., & Nappi, G. (1998). Premenstrual Syndrome and Anxiety Disorders: A Psychobiological Link. Psychotherapy and Psychosomatics. https://doi.org/10.1159/000012260
117. Falcão, F. A., Santos, A. L. D., Barbosa, D. C. B., & Santos, T. R. D. (2022). Responsabilidade civil no erro médico e dano moral. AYA Editora eBooks. https://doi.org/10.47573/aya.5379.2.95.25
118. Falk, M. J., & Moreno, M. A. (2019). What Parents Need to Know About Genetic Testing. JAMA Pediatrics. https://doi.org/10.1001/jamapediatrics.2019.0005
119. Fama, J. M., & Wilhelm, S. (2010). Obsessions. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0616
120. Fernandes, C. E., Ferreira, J. A. D. S., Azevedo, L. H. D., Pellini, E. A. J., & Peixoto, S. V. (2004). Síndrome da tensão pré-menstrual – o estado atual dos conhecimentos. Arquivos Médicos do ABC.
121. Feteih, A., Zhang, L., Tardio, N., & Fein, M. (2021). Exercise-Induced Anaphylaxis (EIA) and Food-Dependent EIA (FDEIA). CRC Press eBooks. https://doi.org/10.1201/9781003174202-17
122. Fiebai, P. O., Ukueku, A. O., & Ogu, R. (2019). Pre Menstrual Syndrome. IntechOpen eBooks. https://doi.org/10.5772/intechopen.80492
123. Fine, L., Dubrovsky, B., & Spielman, A. J. (2011). Insomnia. BENTHAM SCIENCE PUBLISHERS eBooks. https://doi.org/10.2174/978160805153311101010137
124. Fink, M. (2010). Depressive Mood Disorders. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780195365740.003.0009
125. Fink, M. (2010). Movement Disorders. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780195365740.003.0011
126. Fisher, R. L. (2022). Premenstrual Dysphoric Disorder (PMDD). CRC Press eBooks. https://doi.org/10.1201/9781003039235-41
127. Fisher, R. L. (2022). Premenstrual Syndrome (PMS). CRC Press eBooks. https://doi.org/10.1201/9781003039235-42
128. Fitzgerald, C., & Patten, S. B. (2008). Is Multiple Sclerosis Patient Depressed, Stressed, or Both? How to Sort through Overlapping Symptoms and Provide Appropriate Treatment. Current psychiatry.
129. Flier, S. N., & Rose, S. (2006). Is Functional Dyspepsia of Particular Concern in Women? A Review of Gender Differences in Epidemiology, Pathophysiologic Mechanisms, Clinical Presentation, and Management. The American Journal of Gastroenterology. https://doi.org/10.1111/j.1572-0241.2006.01015.x
130. Flier, S. N., & Rose, S. (2006). Is Functional Dyspepsia of Particular Concern in Women? A Review of Gender Differences in Epidemiology, Pathophysiologic Mechanisms, Clinical Presentation, and Management. The American Journal of Gastroenterology. https://doi.org/10.14309/00000434-200612001-00009
131. Fois, A. (2014). Early infantile epileptic encephalopathies. The Italian Journal of Pediatrics/Italian journal of pediatrics. https://doi.org/10.1186/1824-7288-40-s1-a69
132. Fowler, A. W. (2003). Patients need comfort and control in beds and chairs. BMJ. https://doi.org/10.1136/bmj.327.7427.1349-b
133. Frable, M. A. S. (1962). Hoarseness, a Symptom of Premenstrual Tension. Archives of Otolaryngology - Head and Neck Surgery. https://doi.org/10.1001/archotol.1962.00740040070006
134. Frable, M. A. S. (1962). HOARSENESS, A SYMPTOM OF PREMENSTRUAL TENSION. Obstetrical & Gynecological Survey. https://doi.org/10.1097/00006254-196206000-00026
135. Frank, E. P. (1986). What Are Nurses Doing to Help PMS Patients?. AJN American Journal of Nursing. https://doi.org/10.2307/3425004
136. Franz, M. R., & Schepank, H. (1997). [Mood disorders. Prevalence and course of unspecified functional disorders from the epidemiologic and psychosomatic viewpoint].. PubMed.
137. Fried, I., Fahoum, F., Frew, A. J., Andelman, F., Andelman‐Gur, M. M., & Salamon, N. (2021). Laser ablation of human guilt. Brain stimulation. https://doi.org/10.1016/j.brs.2021.11.020
138. Frisbee, J. C., Brooks, S., Stanley, S., & d’Audiffret, A. C. (2015). An Unpredictable Chronic Mild Stress Protocol for Instigating Depressive Symptoms, Behavioral Changes and Negative Health Outcomes in Rodents. Journal of Visualized Experiments. https://doi.org/10.3791/53109
139. Frisbee, J. C., Brooks, S., Stanley, S., & d’Audiffret, A. C. (2015). An Unpredictable Chronic Mild Stress Protocol for Instigating Depressive Symptoms, Behavioral Changes and Negative Health Outcomes in Rodents. Journal of Visualized Experiments. https://doi.org/10.3791/53109-v
140. Fukudo, S., Muranaka, M., Nomura, T., & Satake, M. (1992). [Brain-gut interactions in irritable bowel syndrome: physiological and psychological aspect].. PubMed.
141. Gailliot, M. T., Hildebrandt, B. A., Eckel, L. A., & Baumeister, R. F. (2010). A Theory of Limited Metabolic Energy and Premenstrual Syndrome Symptoms: Increased Metabolic Demands during the Luteal Phase Divert Metabolic Resources from and Impair Self-Control. Review of General Psychology. https://doi.org/10.1037/a0018525
142. Galvez-Sánchez, C. M., Duschek, S., & Paso, G. A. R. D. (2019). &lt;p&gt;Psychological impact of fibromyalgia: current perspectives&lt;/p&gt;. Psychology Research and Behavior Management. https://doi.org/10.2147/prbm.s178240
143. Gani, R., & Bhat, Z. A. (2018). None. International Journal of Pharmaceutical Sciences and Research. https://doi.org/10.13040/ijpsr.0975-8232.9(3).844-53
144. Garcia, P. A. G., & Martinez, A. C. L. (2019). Síndrome de alienación parental: consecuencias en los hijos a nivel psicológico..
145. García, M. D. S., & Calderón, R. M. (2010). Síntomas no motores en la enfermedad de Parkinson y estimulación cerebral profunda. Revista de Neurología. https://doi.org/10.33588/rn.50s02.2009745
146. Gibaja-Reyes, D., Carpio, G. R.-D., Pacheco-Zuel, E., Caso-Rodríguez, M., & Cruz-Sotomayor, A. (2021). Galactorrea euprolactinémica en una adolescente con depresión: Reporte de caso. Revista de Neuro-Psiquiatría. https://doi.org/10.20453/rnp.v84i3.4038
147. Gilman, M. (2015). Breath holding: an elusive obstacle. Voice and Speech Review. https://doi.org/10.1080/23268263.2015.1085719
148. Gilson, R. (1996). Hepatitis B and admission to medical school. BMJ. https://doi.org/10.1136/bmj.313.7061.830
149. Gjerdingen, D. K., Froberg, D. G., & Wilson, D. L. (1986). Postpartum mental and physical problems. Postgraduate Medicine. https://doi.org/10.1080/00325481.1986.11699637
150. Glasgow, H. B., Burkholder, J. M., Schmechel, D. E., Tester, P. A., & Rublee, P. A. (1995). Insidious effects of a toxic estuarine dinoflagellate on fish survival and human health. Journal of Toxicology and Environmental Health. https://doi.org/10.1080/15287399509532051
151. González, A. (2005). Fisiopatología y diagnóstico de la anorexia nerviosa y la bulimia.
152. González, M. F. A. (2019). DETERMINACIÓN DE LOS EFECTOS FISIOLÓGICOS CAUSADOS POR ESTRÉS ACADÉMICO Y LABORAL EN ESTUDIANTES DE QUÍMICA Y QUÍMICO FARMACÉUTICO BIOLÓGO.
153. Goodyer, I., Herbert, J., Tamplin, A. K., & Altham, P. M. E. (2000). Recent life events, cortisol, dehydroepiandrosterone and the onset of major depression in high-risk adolescents. The British Journal of Psychiatry. https://doi.org/10.1192/bjp.177.6.499
154. Grabowska–Grzyb, A. (2005). Zaburzenia psychiczne w padaczce. Polski Przegląd Neurologiczny.
155. Greist, J. H. (1995). The diagnosis of social phobia.. PubMed.
156. Grieco, J. A., Pulsifer, M. B., Seligsohn, K., Skotko, B. G., & Schwartz, A. (2015). Down syndrome: Cognitive and behavioral functioning across the lifespan. American Journal of Medical Genetics Part C Seminars in Medical Genetics. https://doi.org/10.1002/ajmg.c.31439
157. Groisman, A. E., & Seminatore, M. L. (2003). Children and Adolescents Who Have Schizophrenia. Pediatrics in Review. https://doi.org/10.1542/pir.24.10.356
158. Gupta, K., & Mamidi, P. (2022). Madonmada of Bhela samhita. Journal of Applied Consciousness Studies. https://doi.org/10.4103/ijoyppp.ijoyppp_16_21
159. Guskiewicz, K. M., & Goldman, S. B. (2013). A Changing Landscape: Traumatic Brain Injury in Military Combat and Civilian Athletics. The FASEB Journal. https://doi.org/10.1096/fj.13-1101ufm
160. Hadi, A. H., & Kzar, M. H. (2015). The Effect of Physical Effort on Some Blood Components and the Level of Dyspnea in Patients with Chest Wall Disease for Smokers and Non-Smokers. International Journal of Advanced Sport Sciences Research.
161. Hadi, I., Wijayati, F., Usman, R. D., & Rosyanti, L. (2017). Major Depressive Disorder: A Mini Review. Health Information Jurnal Penelitian. https://doi.org/10.36990/hijp.v9i1.102
162. Halbreich, U. (1995). Premenstrual Dysphoric Disorders, Anxiety, and Depressions: Vulnerability Traits or Comorbidity. Archives of General Psychiatry. https://doi.org/10.1001/archpsyc.1995.03950190088013
163. Halbreich, U. (1997). Premenstrual dysphoric disorders: a diversified cluster of vulnerability traits to depression. Acta Psychiatrica Scandinavica. https://doi.org/10.1111/j.1600-0447.1997.tb09616.x
164. Hales, R. E., & Yudofsky, S. C. (1996). Synopsis of psychiatry.
165. Halligan, S. L. (2014). Neurobiological outcomes in the offspring of postnatally depressed mothers: Causes and consequences. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780199676859.003.0019
166. Hansson, E. E., Månsson, N.-O., & Håkansson, A. (2005). Assessment and management of vertigo and dizziness among older persons. Reviews in Clinical Gerontology. https://doi.org/10.1017/s0959259805001565
167. Harvey, P. D. (2010). Schizophrenia, Functional Outcomes in. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0822
168. Hasanat, N. U., & Ma, S. (2015). Pengembangan Modul untuk Meningkatkan Emosi Positif Pasien di Rumah Sakit. Buletin Psikologi. https://doi.org/10.22146/bpsi.7446
169. Hatcher-Kay, C., & King, C. A. (2003). Depression and Suicide. Pediatrics in Review. https://doi.org/10.1542/pir.24-11-363
170. Hatcher-Kay, C., & King, C. A. (2003). Depression and Suicide. Pediatrics in Review. https://doi.org/10.1542/pir.24.11.363
171. Hawkes, M. A., & Hocker, S. E. (2021). Status Epilepticus. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197512166.003.0057
172. Hensley, P. L., & Clayton, P. J. (2008). Bereavement: Signs, Symptoms, and Course. Psychiatric Annals. https://doi.org/10.3928/00485713-20081001-04
173. Heppenstall, C. P., Wilkinson, T., Hanger, H., & Keeling, S. (2009). Frailty: dominos or deliberation?. PubMed.
174. Hernández, Y. D. C. S. (2016). Alteraciones estructurales de las regiones cerebrales sexuales tras empleo de paroxetina versus agomelatina. https://doi.org/10.14201/gredos.129703
175. Hiro, H., & Nagata, M. (2015). Support of workers with Developmental Disorders. Stress Science Research. https://doi.org/10.5058/stresskagakukenkyu.30.35
176. Hirschfeld, R. M. A., Calabrese, J. R., Frye, M. A., Lavori, P. W., Sachs, G., Thase, M. E., & Wagner, K. D. (2007). Defining the clinical course of bipolar disorder: response, remission, relapse, recurrence, and roughening.. PubMed.
177. Hlodak, J., Gecková, A. M., Veselská, Z. D., & Feketeová, E. (2025). The burden of narcolepsy symptoms from patients’ perspective: a narrative qualitative study. Sleep And Breathing. https://doi.org/10.1007/s11325-025-03407-y
178. Ho, M.-K., & Siu, A. Y.-C. (2010). High Altitude Medicine.
179. Holtmann, G., Shah, A., & Morrison, M. (2017). Pathophysiology of Functional Gastrointestinal Disorders: A Holistic Overview. Digestive Diseases. https://doi.org/10.1159/000485409
180. Hou, S., & Rabchevsky, A. G. (2014). Autonomic Consequences of Spinal Cord Injury. Comprehensive physiology. https://doi.org/10.1002/cphy.c130045
181. Hou, S., & Rabchevsky, A. G. (2014). Autonomic Consequences of Spinal Cord Injury. Comprehensive physiology. https://doi.org/10.1002/j.2040-4603.2014.tb00584.x
182. Housley, S. B., Patel, D., Nyabuto, E., & Reynolds, R. M. (2021). Spinal cord detethering without laminectomy or laminotomy. Surgical Neurology International. https://doi.org/10.25259/sni_942_2021
183. Huda, A. S. (2019). Social factors and health. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198807254.003.0013
184. Hudson, A., Taylor, D., Lee, K. A., & Gilliss, C. L. (2005). Symptom experience and self-care strategies among healthy, midlife African-American women.. PubMed.
185. Hvolby, A., Jørgensen, J., & Bilenberg, N. (2005). [Sleeping disorders can imitate attention deficit/hyperactivity disorder].. PubMed.
186. Häuser, W., Dinkel, A., & Lahmann, C. (2012). Funktionelle gastrointestinale Störungen. Psychiatrie und Psychotherapie up2date. https://doi.org/10.1055/s-0032-1304958
187. Iliev, B., & Pavlovska, I. (2021). Analysis of Clinical Features of Patients with Depressive Disorder. Journal of Health Medicine and Nursing. https://doi.org/10.7176/jhmn/92-01
188. Insel, T. R., Zahn, T. P., & Murphy, D. L. (2019). Obsessive-Compulsive Disorder. Routledge eBooks. https://doi.org/10.4324/9780203728215-40
189. Ivada, P. F., Ardani, I. G. A. I., Lesmana, C. B. J., Windiani, I. G. A. T., Adnyana, I. G. A. N. S., & Fithriyah, I. (2022). Quality of life of pediatric patients experiencing organic depressive disorder with Juvenile Idiopathic Arthritis. International journal of health & medical sciences. https://doi.org/10.21744/ijhms.v5n4.1994
190. Jain, S., Goel, S., & Kapila, S. (2015). Clinical Evaluation Of Psychiatric Emergencies.
191. Jimenez, B., & Lechuga, Y. A. (2019). La importancia del sueño en la vida cotidiana.
192. Jobe, A., Lewis, D., Wainwright, M. S., & DeLong, G. R. (2000). Three Children With a Syndrome of Obesity and Overgrowth, Atypical Psychosis, and Seizures: A Problem in Neuropsychopharmacology. Journal of Child Neurology. https://doi.org/10.1177/088307380001500805
193. Kamlana, S. H., & Holms, L. (1986). Paranoid Reaction and Underlying Thyrotoxicosis. The British Journal of Psychiatry. https://doi.org/10.1192/bjp.149.3.376
194. Kanyengo, C. W. (2009). Zambia: The challenge of informing blind and deaf clients.
195. Katz, D. I., Alexander, M. P., & Mandell, A. M. (1987). Dementia Following Strokes in the Mesencephalon and Diencephalon. Archives of Neurology. https://doi.org/10.1001/archneur.1987.00520230017007
196. Katzman, M. A. (2021). The Diagnosis of Major Depressive Disorder is based on the Person's Reported Experiences and a Mental Status Examination. Journal of Aging and Geriatric Medicine.
197. Kazymova, N., Kharlamenkova, N. Y., & Nikitina, D. A. (2019). Severe life events and their psychological consequences: loss or threat of loss of nearest. Vestnik Kostroma State University Series Pedagogy Psychology Sociokinetics. https://doi.org/10.34216/2073-1426-2019-25-2-96-101
198. Kefelja, M. (2018). Depresija u starijoj životnoj dobi.
199. Kehl, K. A. (2008). Caring for the Patient and the Family in the Last Hours of Life. Home Health Care Management & Practice. https://doi.org/10.1177/1084822303311839
200. Kehl, K. A. (2008). Caring for the Patient and the Family in the Last Hours of Life. Home Health Care Management & Practice. https://doi.org/10.1177/1084822307311839
201. Kelly, F. D. (2010). Adjustment Disorder. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0015
202. Kelly, P. (2012). Posttraumatic Stress Disorder. Pediatrics in Review. https://doi.org/10.1542/pir.33.8.382
203. Kennedy, J. E., Jaffee, M. S., & Cooper, D. (2013). Posttraumatic Stress Disorder. American Psychiatric Publishing eBooks. https://doi.org/10.1176/appi.books.9781585625154.da08
204. Kennedy, S. H. (2008). Core symptoms of major depressive disorder: relevance to diagnosis and treatment. Dialogues in Clinical Neuroscience. https://doi.org/10.31887/dcns.2008.10.3/shkennedy
205. Khaikin, Y., & Mercimek‐Andrews, S. (2016). STXBP1 Encephalopathy with Epilepsy.
206. Khan, I., & Khan, M. A. (2021). Sensory and Perceptual Alterations. StatPearls.
207. Khan, S. I. (2021). Loss of appetite.. Preventive Nutrition and Food Science.
208. Kiecolt‐Glaser, J. K., Derry, H. M., & Fagundes, C. P. (2015). Inflammation: Depression Fans the Flames and Feasts on the Heat. American Journal of Psychiatry. https://doi.org/10.1176/appi.ajp.2015.15020152
209. Kim, H. A., Bisdorff, A., Bronstein, A. M., Lempert, T., Rossi-Izquierdo, M., Staab, J. P., Strupp, M., & Kim, J. (2019). Hemodynamic orthostatic dizziness/vertigo: Diagnostic criteria. Journal of Vestibular Research. https://doi.org/10.3233/ves-190655
210. Kim, S.-H. (2015). Neurogenic Bladder Dysfunction Caused by Seronegative Autoimmune Autonomic Ganglionopathy. Soonchunhyang Medical Science. https://doi.org/10.15746/sms.15.010
211. Kirby, N., Kilsby, A., & Walker, R. (2019). Assessing low mood during pregnancy. BMJ. https://doi.org/10.1136/bmj.l4584
212. Klein, S. (2015). Autistic phenomena in neurotic patients 1. Routledge eBooks. https://doi.org/10.4324/9781315743882-10
213. Knorring, L. V., Almay, B. G. L., Ekman, R., & Widerlöv, E. (1988). Biological markers in chronic pain syndromes. Nordisk Psykiatrisk Tidsskrift. https://doi.org/10.3109/08039488809103219
214. Koch, K. L., & Stern, R. M. (1996). Functional disorders of the stomach.. PubMed.
215. Koffel, E., & Watson, D. (2010). Unusual sleep experiences, dissociation, and schizotypy. https://doi.org/10.17077/15jq-9y57
216. Konez, O., Pascual-Castroviejo, I., Rocco, C. D., & Ruggieri, M. (2008). Sturge-Weber Syndrome. https://doi.org/10.1007/978-3-211-69500-5_10
217. Korzekwa, M., & Steiner, M. (1997). Premenstrual Syndromes. Clinical Obstetrics & Gynecology. https://doi.org/10.1097/00003081-199709000-00017
218. Kotade, K. B., Pandit, B. S., Gaware, V. M., Dolas, R. T., Dhamak, K. B., Somwanshi, S. B., Nikam, V. K., & Khadse, A. N. (2011). KNOWING DEPRESSION AND PHARMACOLOGICAL, NON-PHARMACOLOGICAL APPROACHES FOR ITS TREATMENT.
219. Kovács, Z., Hegyi, G., & Szôke, H. (2022). Premenstruális szindróma és premenstruális dysphoriás zavar.. Orvosi Hetilap. https://doi.org/10.1556/650.2022.32496
220. Kumar, A. (2019). None. Current Trends On Biotechnology & Microbiology Open Access Publishers. https://doi.org/10.32474/ctbm.1.2
221. Kumar, G. P., Krishna, P. Y., Manisha, D., Singh, G., Khushboo, A., & Ps, M. (2015). ROLE OF MANAS BHAVA IN THE ETIOPATHOGENESIS OF AMLAPITTA IN CONTEXT OF HYPERACIDITY.
222. Kumar, M. S. (2006). Low Iron Status: A Possible Risk Factor for First Febrile Seizure.
223. Kumar, P., Bhaskar, M., & Soni, A. (2019). PRIMARY VERSUS SECONDARY PSYCHIATRIC DISORDERS: A TYPICAL CASE PRESENTATION. Indian Journal of Case Reports. https://doi.org/10.32677/ijcr.2019.v05.i02.016
224. Lahey, B. B. (2021). Dimensions of Externalizing Problems. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197607909.003.0004
225. Lalani, S. R., Graham, B. H., Burrage, L. C., Lai, Y., Scaglia, F., Soler‐Alfonso, C., Miyake, C. Y., & Yang, Y. (2018). TANGO2-Related Metabolic Encephalopathy and Arrhythmias. University of Washington, Seattle eBooks.
226. Lam, R. W. (2012). Clinical features and diagnosis. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199692736.003.0004
227. Lam, R. W. (2018). Associated clinical features. Depression. https://doi.org/10.1093/med/9780198804147.003.0005
228. Lam, R. W. (2018). Clinical features and diagnosis. Depression. https://doi.org/10.1093/med/9780198804147.003.0004
229. Lavin, M. (2010). Voyeurism. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy1030
230. Lawrie, S. M. (2010). Schizophrenia, bipolar disorder, obsessive–compulsive disorder, and personality disorder. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199204854.003.260507
231. Ledezma, C., Soto, K., & Suárez, M. I. (2015). Depresión en el adulto mayor en Costa Rica: un problema social. Revista Hispanoamericana de Ciencias de la Salud.
232. Leitzelar, B. N., & Koltyn, K. F. (2021). Exercise and Neuropathic Pain: A General Overview of Preclinical and Clinical Research. Sports Medicine - Open. https://doi.org/10.1186/s40798-021-00307-9
233. Leoni, M. C., Pizzo, D., Rundo, B., Tasso, G., & Marchi, A. (2009). Atassia in ex-prematuro: un caso pediatrico. Bollettino della Società Medico Chirurgica di Pavia. https://doi.org/10.6092/2039-1404.122.404
234. Lečić-Toševski, D. M., Pejović-Milovančević, M., Popović-Deušić, S., & Šušić (2007). [Psychiatric aspects of sleep].. PubMed.
235. Lipschutz, R., Ravi, M., Lathan, E. C., Duan, M., Karra, S., Wallace, S., Arthur, M., Britt, A., Powers, A., & Michopoulos, V. (2025). Associations between pre- and postpartum posttraumatic stress symptoms and maternal functioning in Black trauma-exposed women. Journal of Mood and Anxiety Disorders. https://doi.org/10.1016/j.xjmad.2025.100111
236. Lucas, A. L. (2014). Approach to Nausea and Vomiting. https://doi.org/10.1002/9781118932759.ch2
237. Lucena, A. C. D. A., Lopes, E. D. A. N., Marinho, F. M. D. S., & Pelo, M. V. G. (2022). Fatores que influenciam para o desenvolvimento da depressão na gestação. AYA Editora eBooks. https://doi.org/10.47573/aya.5379.2.95.1
238. Luecha, A. (1998). Dietary Modifications Can Help Alleviate Symptoms of PMS.
239. López, R. M. (2018). LOS TRASTORNOS DE ANSIEDAD, PROBLEMAS DE SALUD PÚBLICA. PALPITACIONES, OPRESIÓN EN EL PECHO Y SUDORACIÓN EN LAS MANOS, ENTRE OTROS. Gaceta UNAM (2010-2016).
240. L�pine, J.-P., & Briley, M. (2004). The epidemiology of pain in depression. Human Psychopharmacology Clinical and Experimental. https://doi.org/10.1002/hup.618
241. Maccari, S., Krugers, H. J., Morley‐Fletcher, S., Szyf, M., & Brunton, P. J. (2014). The Consequences of Early‐Life Adversity: Neurobiological, Behavioural and Epigenetic Adaptations. Journal of Neuroendocrinology. https://doi.org/10.1111/jne.12175
242. Machado, C. F. A., & Siqueira, E. C. D. (2022). Uma abordagem geral do Transtorno de Estresse Pós-Traumático: revisão de literatura. Revista Eletrônica Acervo Médico. https://doi.org/10.25248/reamed.e10939.2022
243. Macneil, C., Hasty, M., Conus, P., Berk, M., & Scott, J. (2009). Social rhythm regulation. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511757389.008
244. MacPherson, H. A. (2019). More than medication: The importance of family treatments for pediatric bipolar disorder. The Brown University Child and Adolescent Behavior Letter. https://doi.org/10.1002/cbl.30433
245. Macêdo, R. A. F. (2022). A importância da orientação vocacional/profissional para o direcionamento de carreira na adolescência. AYA Editora eBooks. https://doi.org/10.47573/aya.5379.2.95.18
246. Madrid, P. A., Grant, R., Reilly, M. J., & Redlener, N. B. (2006). Challenges in Meeting Immediate Emotional Needs: Short-term Impact of a Major Disaster on Children's Mental Health: Building Resiliency in the Aftermath of Hurricane Katrina. PEDIATRICS. https://doi.org/10.1542/peds.2006-0099u
247. Madruga, M. L. L. H., Melo, G. B., Martins, J. M., Aranha, R. E. L. D. B., Marinho, J. C. R. L., Alves, N. T., Estudo, E., Revisão, U., & Literatura, D. (2018). Estudo Eletroencefalográfico De Indivíduos Com Dor Crônica Decorrente Da Fibromialgia: Uma Revisão Da Literatura. Scientific Research and Reviews. https://doi.org/10.28933/srr-2018-06-28100
248. Mahon, K., Arnold, R. W., & Koller, H. P. (2007). Symptomatic Convergence Insufficiency. Journal of Pediatric Ophthalmology & Strabismus. https://doi.org/10.3928/01913913-20070701-12
249. Mahon, S. M., & Carr, E. (2021). Fatigue/Lack of Endurance: Common Side Effect. Clinical journal of oncology nursing. https://doi.org/10.1188/21.cjon.s2.25
250. Maj, M. (2015). "Mixed" Depression: Drawbacks of &lt;em&gt;DSM-5&lt;/em&gt; (and Other) Polythetic Diagnostic Criteria. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.14com09487
251. Maki, P. M., Kornstein, S. G., Joffe, H., Bromberger, J. T., Freeman, E. W., Athappilly, G., Bobo, W. V., Rubin, L. H., Koleva, H., Cohen, L. S., & Soares, C. N. (2018). Guidelines for the Evaluation and Treatment of Perimenopausal Depression: Summary and Recommendations. Journal of Women s Health. https://doi.org/10.1089/jwh.2018.27099.mensocrec
252. Marsh, T. D. (1999). Irritable Bowel Syndrome. Journal of Pharmacy Practice. https://doi.org/10.1177/089719009901200605
253. Martens, W. H. J., & Kahn, W. A. (2003). Emotional Capacities and Sensitivity in Psychopaths.
254. María, A., Sancho, R., & Pita, B. L. (2005). Trastornos de ansiedad en la infancia y en la adolescencia.
255. Massil, H., & Brien, P. M. S. O. (1987). Approach To The Management of Premenstrual Syndrome. Clinical Obstetrics & Gynecology. https://doi.org/10.1097/00003081-198706000-00024
256. Master, C. L., Bacal, D., Grady, M. F., Hertle, R. W., Shah, A. S., Strominger, M. B., Whitecross, S., Bradford, G. E., Lum, F., & Donahue, S. P. (2022). Vision and Concussion: Symptoms, Signs, Evaluation, and Treatment. PEDIATRICS. https://doi.org/10.1542/peds.2021-056047
257. Matsui, Y. (2016). [Pathological state or cause of sarcopenia.]. PubMed.
258. Mavridis, I. N., Meliou, M., & Pyrgelis, E. (2017). Presenting Symptoms of Pituitary Apoplexy. Journal of Neurological Surgery Part A Central European Neurosurgery. https://doi.org/10.1055/s-0037-1599051
259. Mayer, E. A., & Tillisch, K. (2010). The Brain-Gut Axis in Abdominal Pain Syndromes. Annual Review of Medicine. https://doi.org/10.1146/annurev-med-012309-103958
260. Mayer, E., Fass, R., & Fullerton, S. (1998). Intestinal and Extraintestinal Symptoms in Functional Gastrointestinal Disorders. The European Journal of Surgery. https://doi.org/10.1080/11024159850191201
261. McCrory, P., Meeuwisse, W., Echemendía, R. J., Iverson, G. L., Dvořák, J., & Kutcher, J. S. (2013). What is the lowest threshold to make a diagnosis of concussion?. British Journal of Sports Medicine. https://doi.org/10.1136/bjsports-2013-092247
262. Medina-Chávez, J. H., Fuentes-Alexandro, S., Gil-Palafox, I. B., Adame-Galván, L., Solís-Lam, F., Sánchez-Herrera, L. Y., & Narváez, F. S. (2014). [Clinical practice guideline. Diagnosis and treatment of insomnia in the elderly].. PubMed.
263. Medina-Chávez, J. H., Fuentes-Alexandro, S., Gil-Palafox, I. B., Adame-Galván, L., Solís-Lam, F., Sánchez-Herrera, L. Y., & Narváez, F. S. (2014). Diagnóstico y tratamiento del insomnio en el adulto mayor.
264. Mellero, D. (2007). Ansiedade em situações de convívio social em idosos.
265. Mensack, S. (2021). Respiratory Alkalosis. Critical care. https://doi.org/10.1201/9781315140629-19
266. Mervis, C. Β., Morris, C. A., Klein-Tasman, B., Velleman, S. L., & Osborne, L. R. (2015). 7q11.23 Duplication Syndrome.
267. Meyer, J. S., & Hamel, A. F. (2014). Models of Stress in Nonhuman Primates and Their Relevance for Human Psychopathology and Endocrine Dysfunction. ILAR Journal. https://doi.org/10.1093/ilar/ilu023
268. Mian, N. D., & Carter, A. S. (2013). Recognition and Assessment of Anxiety & Depression in Early Childhood.
269. Michiels, J., Berneman, Z., Gadisseur, A., Lam, K. H., Raeve, H. D., & Schroyens, W. (2014). Aspirin-Responsive, Migraine-Like Transient Cerebral and Ocular Ischemic Attacks and Erythromelalgia in JAK2&lt;sup&gt;V617F&lt;/sup&gt;-Positive Essential Thrombocythemia and Polycythemia Vera. Acta Haematologica. https://doi.org/10.1159/000360388
270. Milano, W., Ambrosio, P., Carizzone, F., Biasio, V. D., Foia, M. G., Saetta, B., Milano, M. F., & Capasso, A. (2021). Menstrual Disorders Related to Eating Disorders. Endocrine Metabolic & Immune Disorders - Drug Targets. https://doi.org/10.2174/1871530321666210625145345
271. Miller, A. E., DeAngelis, T. M., Fabian, M., & Sand, I. K. (2018). Recurrent Ulcers and a Brainstem Lesion. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190693190.003.0007
272. Miller, M. W., Marx, B. P., & Keane, T. M. (2010). Posttraumatic Stress Disorder. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0699
273. Mills, D. S. (2014). Clinical animal behaviour models of stereotypic behaviour and underlying cognition.
274. Modebelu, U., Nargarathan, P. K. M., Marleime, K., & Ramesh, K. (2019). Pharmacologic Therapy for Neonatal Abstinence Syndrome. Journal of Drug Delivery and Therapeutics. https://doi.org/10.22270/jddt.v9i3.2900
275. Modell, M., Mughal, Z., & Boyd, R. (1996). Recurrent pains. https://doi.org/10.1093/oso/9780192625120.003.0019
276. Mohammadi, M. R., & Akhondzadeh, S. (2007). Pharmacotherapy of attention-deficit/hyperactivity disorder: nonstimulant medication approaches. Expert Review of Neurotherapeutics. https://doi.org/10.1586/14737175.7.2.195
277. Mohiuddin, A. K. (2019). Complimentary Care: Non-Pharmacological Pain Management. International Journal of Pain Research and Treatment. https://doi.org/10.28933/ijprt-2019-07-2005
278. Montalto, S. A. (2021). Intrapartum Asphyxia and Its Sequelae. Cambridge University Press eBooks. https://doi.org/10.1017/9781108863049.061
279. Moore, D. P., & Puri, B. K. (2012). Textbook of Clinical Neuropsychiatry and Behavioral Neuroscience 3E.
280. Moshki, M., & Kharazmi, A. (2015). Application of the PRECEDE Model to Understanding Postnatal Depression.. PubMed.
281. Mott, J., & Morrison, J. A. (2019). Hypertension, Portal. Blackwell's Five‐Minute Veterinary Consult Clinical Companion. https://doi.org/10.1002/9781119376293.ch130
282. Mucci, V., Sussetto, M., Ranieri, M., Cavuscens, S., Fornos, A. P., & Guinand, N. (2019). [The Mal de Débarquement Syndrome].. PubMed.
283. Mulak, A. (2003). Testing of visceral sensitivity.. Journal of Physiology and Pharmacology.
284. Munir, S., & Takov, V. (2021). Generalized Anxiety Disorder. StatPearls.
285. Munir, S., Takov, V., & Coletti, V. A. (2021). Generalized Anxiety Disorder (Nursing).
286. Murakami, M., & Matsuno, T. (2010). Musculoskeletal Chronic Pain and Psychosocial Stress. Journal of Nihon University Medical Association. https://doi.org/10.4264/numa.69.183
287. Mut, E. A., Pălădoiu, C., & Stănescu, M. (2021). Somatoform and conversion disorders as psychological defences. Journal of Educational Sciences & Psychology. https://doi.org/10.51865/jesp.2021.1.19
288. Muzik, M., Marcus, S. M., Flynn, H. A., & Rosenblum, K. L. (2010). Depression during pregnancy: detection, comorbidity and treatment. Asia-Pacific Psychiatry. https://doi.org/10.1111/j.1758-5872.2010.00051.x
289. Nadeem, M. S., Murtaza, B. N., Al-Ghamdi, M. A., Ali, A., Zamzami, M. A., Khan, J. A., Ahmad, A., Rehman, M. U., & Kazmi, I. (2021). Autism - A Comprehensive Array of Prominent Signs and Symptoms. Current Pharmaceutical Design. https://doi.org/10.2174/1381612827666210120095829
290. Naidoo, S. (2015). Managing stress in the dental environment.
291. Nakayama, H., Mihara, S., Sakuma, H., Kitamura, D., & Higuchi, S. (2014). SY08-3 * CO-MORBIDITY OF INTERNET ADDICTION. Alcohol and Alcoholism. https://doi.org/10.1093/alcalc/agu052.39
292. Nanagas, M. T. (2011). Bipolar Disorders. Pediatrics in Review. https://doi.org/10.1542/pir.32.11.502
293. Nasrallah, H. A. (2014). Borderline Personality Disorder Is a Heritable Brain Disease. Current psychiatry.
294. Nava, G. M. (2018). Depression: From Sorrow to Melancholia. Scholarly Journal of Psychology and Behavioral Sciences. https://doi.org/10.32474/sjpbs.2018.01.000106
295. Nazari, M., Rajabzadeh, H., Dadkhah, M., Boustani, A., & Kor, N. M. (2015). Influences of prenatal and postnatal stress on cognitive function and fear memory consolidation. Scientific Journal of Animal Science. https://doi.org/10.14196/sjbs.v4i8.2076
296. Nielen, M. M. A. (2003). Where emotion meets cognition: studies on executive function in obsessive-compulsive disorder.
297. Nielsen, J. F., Klemar, B., Hansen, H., & Sinkjær, T. (1995). A new treatment of spasticity with repetitive magnetic stimulation in multiple sclerosis.. Journal of Neurology Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp.58.2.254-a
298. Niggemann, B. (2011). Introductory lecture: Diagnosis of food allergy: when is an oral challenge positive. Clinical and Translational Allergy. https://doi.org/10.1186/2045-7022-1-s1-s43
299. Nishino, S., & Fujiki, N. (2006). Animal models for sleep disorders. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511541742.029
300. Nonacs, R., & Cohen, L. S. (1998). Postpartum mood disorders: diagnosis and treatment guidelines.. PubMed.
301. Norton, C., Williams, J., Taylor, C., Nunwa, A., & Whayman, K. (2008). Chapter 19 Bowel care and vulnerable groups. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199298655.003.0019
302. Ojha, A., & Kumar, D. (2021). Psychological Factors in Fibromyalgia and Chronic Fatigue Syndrome: Implications in Counseling. https://doi.org/10.56173/bjcp.2021.1102
303. Oliveira, S., Canha, J., & Pereira, S. P. (2013). 2362 – Is it a prodrome of psychosis? Or is it naanxious disorder? A case report. European Psychiatry. https://doi.org/10.1016/s0924-9338(13)77202-x
304. Olmedo, A., & Rolando, M. (2015). Informe psicológico pericial: situación de violencia intrafamiliar, “maltrato física, psicológica y sexual”, grado de afectación psicológico..
305. Olmos-López, A., Ibarra-Aguilar, J., Cornelio-Nieto, J. O., Ocaña-Hernández, L. A., Márquez-Amaya, M. A., Luna-López, N. A., Reséndiz-Aparicio, J. C., & Rodríguez‐Leyva, I. (2019). Clinical guideline: status epilepticus in children and adults. DELETED. https://doi.org/10.24875/rmn.m19000031
306. Onochie, E., & Verghese, J. (2025). A Case of Depersonalization-Derealization Disorder. BJPsych Open. https://doi.org/10.1192/bjo.2025.10752
307. Osterman, J. E., Erdos, B. Z., Oldham, M., & Ivkovic, A. (2010). Antidepressant Treatments in PTSD. Humana Press eBooks. https://doi.org/10.1007/978-1-60327-435-7_7
308. PADMAWATI, N. N., Ardani, I. G. A. I., Ariyani, A., Ariani, P., & Purnamasidhi, ‪. A. W. (2021). Psychopharmaceutical Therapy and Supportive Psychotherapy for COVID-19 Patients with Depression. International Journal of Medical Reviews and Case Reports. https://doi.org/10.5455/ijmrcr.covid-19-psychopharmaceutical-therapy-172-1608192666
309. Padmos, R. C. (2009). Inflammatory Monocytes in Bipolar Disorder and Related Endocrine Autoimmune Diseases.
310. Pallesen, S., Olsen, O. K., Eide, E. M., Nortvedt, B., Grønli, J., Larøi, F., Nordmo, M., & Glomlien, F. E. (2018). Sleep deprivation and hallucinations. A qualitative study of military personnel. Military Psychology. https://doi.org/10.1080/08995605.2018.1478561
311. Papageorgopoulou, E., & Jones, E. J. H. (2025). Infant Precursors to Autism. Oxford Research Encyclopedia of Psychology. https://doi.org/10.1093/acrefore/9780190236557.013.55
312. Papuc, I., LĂCĂTUŞ, R., Timen, A. M., Coşa, L., & Purdoiu, R. C. (2007). CANINE ANXIETY SINDROME BY DOG - OWNER SEPARATION TREATMENT. Bulletin of University of Agricultural Sciences and Veterinary Medicine Cluj-Napoca Veterinary Medicine. https://doi.org/10.15835/buasvmcn-vm:64:1-2:2397
313. Paredes, D. F. D., Farfán, J. C. P., Orellana, J. M. F., & Legarda, A. A. B. (2019). Trastorno disfórico premenstrual. RECIAMUC. https://doi.org/10.26820/reciamuc/3.(1).enero.2019.199-217
314. PARISER, S. F., Nasrallah, H. A., & Gardner, D. L. (1997). Postpartum Mood Disorders: Clinical Perspectives. Journal of women's health. https://doi.org/10.1089/jwh.1997.6.421
315. Patil, S. R. (2018). TAILA DHARA IN NIDRANASHA W.S.R. TO INSOMNIA. National Journal of Research in Ayurved Science. https://doi.org/10.52482/ayurlog.v6i06.204
316. Pearlstein, T. (2004). PMDD: Definition and Prevalence. CNS Spectrums. https://doi.org/10.1017/s1092852900002005
317. Pearlstein, T. (2006). Will Oral Contraceptives Join SSRIs as a First-Line Treatment Option for Women with Premenstrual Dysphoric Disorder?. Women s Health. https://doi.org/10.2217/17455057.2.2.183
318. Pearlstein, T. (2012). Psychotropic medications and other non-hormonal treatments for premenstrual disorders. Menopause international. https://doi.org/10.1258/mi.2012.012010
319. Pereira, J. A. (2021). Teenager with paranoia and hallucinations preceded by a decline in academic and social functioning. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197577479.003.0006
320. Phillips, K. A. (2014). Body Dysmorphic Disorder. American Psychiatric Publishing eBooks. https://doi.org/10.1176/appi.books.9781585625048.gg22
321. Phillips, K. A. (2014). Body Dysmorphic Disorder: Common, Severe and in Need of Treatment Research. Psychotherapy and Psychosomatics. https://doi.org/10.1159/000366035
322. Phu, T., Remmers, A., Schytz, H. W., Schankin, C. J., Nelson, S. E., Obermann, M., Hansen, J. M., Sinclair, A. J., Gantenbein, A. R., & Schoonman, G. (2018). Red and orange flags for secondary headaches in clinical practice. Neurology. https://doi.org/10.1212/wnl.0000000000006697
323. Piacentini, J., & Bennett, S. M. (2010). Tourette's Disorder. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy1001
324. Pies, R. W. (2007). How Long to Wait for an Antidepressant to 'Work'. Current psychiatry.
325. Pies, R. W. (2007). Is It Bipolar Depression? 'WHIPLASHED' Aids Diagnosis. Current psychiatry.
326. Pompignac, M. (2015). Cas de dépression post-partum chez une femelle orang-outan. Revue de primatologie. https://doi.org/10.4000/primatologie.2169
327. Potvin, O., Hudon, C., Grenier, S., & Préville, M. (2010). Non-essential symptoms of depression and cognitive impairment no dementia (CIND) in community-dwelling elders without dysphoria or anhedonia. International Psychogeriatrics. https://doi.org/10.1017/s1041610210001419
328. Priya, A., Chaturvedi, S., Bhasin, S., Bhatia, M., & Radhakrishnan, G. (2018). Depression, anxiety and stress among pregnant women: A community-based study. Indian Journal of Psychiatry. https://doi.org/10.4103/psychiatry.indianjpsychiatry_230_17
329. Proczkowska‐Björklund, M., Gustafsson, P., & Svedin, C. G. (2010). Children’s play after anaesthesia and surgery: background factors and associations to behaviour during anaesthetic induction. Journal of Child Health Care. https://doi.org/10.1177/1367493509359225
330. Putra, H. G. S. A. (2015). GANGGUAN AFEKTIF BIPOLAR MANIA DENGAN PSIKOTIK: SEBUAH LAPORAN KASUS. DOAJ (DOAJ: Directory of Open Access Journals).
331. Pérez, J. A. H., Botina, A. D. M., Hormiga, M. P., & Sánchez, B. E. B. (2017). Trastornos de la alimentación: Anorexia nerviosa y bulimia nerviosa. RFS Revista Facultad de Salud. https://doi.org/10.25054/rfs.v9i1.1827
332. Quintero, J. M. B., Castellanos, A., & Santos, L. S. D. L. (2018). Efectividad de una intervención pre-quirúrgica de enfermería; en ansiedad de pacientes sometidos a colecistectomía del Hospital General Regional No.1 Vicente Guerrero de Acapulco, 2017.
333. Qureshi, M. A., & Wasti, S. A. (2014). Lay-off Survivor Sickness Syndrome (Investigating the Lasting Impact on Performance of Survivors in the Context of Age and Gender in Private Sector Organizations of Pakistan). International Journal of Human Resource Studies. https://doi.org/10.5296/ijhrs.v4i3.6078
334. Rabiepoor, S., & yas, A. (2018). Awareness, Attitude and Performance of Men Regarding Premenstrual Syndrome. International Journal of Women s Health and Reproduction Sciences. https://doi.org/10.15296/ijwhr.2018.76
335. Rakofsky, J. J., & Dunlop, B. W. (2014). Treating Bipolar Mania in the Outpatient Setting: Enlist the Help of Family, Employ Evidence-Based Pharmacologic and Psychotherapeutic Strategies. Current psychiatry.
336. Rani, M. K. S., Fathima, S. T., Gayathri, S. L., Pavani, M., & Swathi, Y. (2022). Detection of Autism Spectrum Disorder using Machine Learning. International Journal of Advanced Research in Science Communication and Technology. https://doi.org/10.48175/ijarsct-7600
337. Rani, S., & Saini, D. S. (2015). Organizational Stress in Relation to Job Satisfaction and General Health of Professional Women. International journal of education and management studies.
338. Ransom, S. B., & Moldenhauer, J. S. (1998). Premenstrual Syndrome. The Physician and Sportsmedicine. https://doi.org/10.3810/psm.1998.04.872
339. Rapkin, A. J., & Mikacich, J. (2007). Clinical evaluation and management. CRC Press eBooks. https://doi.org/10.3109/9781435628168-19
340. RAPOPORT, J. L., & Fiske, A. P. (1998). The New Biology Of Obsessive-Compulsive Disorder: Implications for Evolutionary Psychology. Perspectives in biology and medicine. https://doi.org/10.1353/pbm.1998.0063
341. Rasgon, N., Shelton, S., & Halbreich, U. (2005). Perimenopausal Mental Disorders: Epidemiology and Phenomenology. CNS Spectrums. https://doi.org/10.1017/s1092852900023166
342. Rasquin‐Weber, A., Hyman, P. E., Cucchiara, S., Fleisher, D. R., Hyams, J. S., Milla, P. J., & Staiano, A. (1999). Childhood functional gastrointestinal disorders. Gut. https://doi.org/10.1136/gut.45.2008.ii60
343. Reddy, M. S. (2014). Irritability as a Criterion in Diagnosis of Child and Adolescent Bipolar Disorder: Thorny Road Ahead. Indian Journal of Psychological Medicine. https://doi.org/10.4103/0253-7176.130954
344. Reid, W. H., Balis, G. U., & Sutton, B. (1997). The treatment of psychiatric disorders : revised for DSM-IV.
345. Reinares, M., Martínez‐Arán, A., & Vieta, E. (2019). Psychoeducation for Patients and Family Members. Cambridge University Press eBooks. https://doi.org/10.1017/9781108589802.004
346. Rengifo, C. A. (2014). Estudio de caso: Trastorno Obsesivo-Compulsivo. Revista de Investigación Universitaria. https://doi.org/10.17162/riu.v3i2.519
347. Rennie, J. M., Hagmann, C., & Robertson, N. J. (2008). The baby with a suspected seizure. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511544750.009
348. Resch, M. (2010). The psychological factors affecting athletic performance. Orvosi Hetilap. https://doi.org/10.1556/oh.2010.28890
349. Rivas-Vazquez, R. A., Carrazana, E., Rey, G., & Wheeler, S. D. (2000). SELECTIVE SEROTONIN REUPTAKE INHIBITOR DISCONTINUATION SYNDROME: THREE CASES PRESENTING TO A NEUROLOGIC PRACTICE. The Neurologist. https://doi.org/10.1097/00127893-200006060-00005
350. Riven, L. (1983). Premenstrual syndrome: a psychological overview.. PubMed.
351. Rodrigues, F. D. A. A. (2022). WHAT HAPPENS IN THE BRAIN OF A PERSON WITH DISORDER. International Journal of Health Science. https://doi.org/10.22533/at.ed.1592442202087
352. Roessner, V., & Rothenberger, A. (2014). Tic Disorders. https://doi.org/10.1007/978-3-7091-1501-5_27
353. Ronad, S. V., Patail, C. S., Gondbal, S. H., TC, K., Ronad, M., Pankaja, T., Badesgol, R., & Singhal, P. K. J. (2019). Professionals in metro cities suffer from anxiety disorder. Nursing & Care Open Access Journal. https://doi.org/10.15406/ncoaj.2019.06.00198
354. Roy, A. (1996). Aetiology of Secondary Depression in Male Alcoholics. The British Journal of Psychiatry. https://doi.org/10.1192/bjp.169.6.753
355. Sahakian, B. J., & Morein‐Zamir, S. (2011). Depression and resilience: insights from cognitive, neuroimaging, and psychopharmacological studies. Oxford University Press eBooks. https://doi.org/10.1093/acprof:oso/9780199600434.003.0023
356. Salcedo, A. K. M., Escobar, J. C. C., & Diaz, L. Y. V. (2019). Ansiedad dental en adultos en la clínica odontológica de la universidad cooperativa de colombia de pasto.
357. Salokangas, R. K. R., & McGlashan, T. H. (2008). Early detection and intervention of psychosis. A review. Nordic Journal of Psychiatry. https://doi.org/10.1080/08039480801984008
358. Santucci, K. T. T., Miranda, A. H., Oliveira, A. J. R., & Vieira, A. F. D. B. (2022). Psicologia organizacional e do trabalho e a humanização no contexto hospitalar. AYA Editora eBooks. https://doi.org/10.47573/aya.5379.2.95.15
359. Sasikumar, B. R. (2011). Low Iron Status: A Possible Risk Factor for First Febrile Seizure.
360. Savino, F., & Oggero, R. (1996). [Management of infantile colics].. PubMed.
361. Sawarkar, A., Shambharkar, R., Shambharkar, M., Khandar, J., Sakharwade, P., & Kasturkar, P. (2021). Case Report on Acute Transient Psychotic Disorder. Journal of Pharmaceutical Research International. https://doi.org/10.9734/jpri/2021/v33i45b32783
362. Sazonov, S. (2014). EPA-0651 – The complexity of psychopathological symptom as a possible indication of mental disease's etiology. European Psychiatry. https://doi.org/10.1016/s0924-9338(14)78023-x
363. Schildkrout, B. (2011). Specific Mental Signs and Symptoms. https://doi.org/10.1002/9781118083598.ch9
364. Schildkrout, B. (2011). Specific Physical Signs and Symptoms. https://doi.org/10.1002/9781118083598.ch7
365. Schildkrout, B. (2014). Delirium. https://doi.org/10.1002/9781394260447.ch2
366. Schildkrout, B. (2014). Disease #35: Migraine. https://doi.org/10.1002/9781394260447.ch63
367. Schildkrout, B. (2014). Disease #47: Parasomnias: Sleepwalking and Night Terrors. https://doi.org/10.1002/9781394260447.ch75
368. Schildkrout, B. (2014). Disease #54: Premenstrual Dysphoric Disorder and Premenstrual Syndrome. https://doi.org/10.1002/9781394260447.ch82
369. Schildkrout, B. (2014). Disease #58: Restless Legs Syndrome. https://doi.org/10.1002/9781394260447.ch86
370. Schildkrout, B. (2014). Hallucinations. https://doi.org/10.1002/9781394260447.ch8
371. Schildkrout, B. (2014). Vegetative Symptoms. https://doi.org/10.1002/9781394260447.ch23
372. Schorb, A., Niebauer, J., Aichhorn, W., Schiepek, G., Scherr, J., & Claussen, M. (2021). Overtraining from a sports psychiatry perspective. German Journal of Sports Medicine. https://doi.org/10.5960/dzsm.2021.496
373. Sekhon, S., Patel, J., & Sapra, A. (2019). Late Onset Depression. StatPearls.
374. Selby, E. A., Panza, E., & Plasencia, M. (2019). Positive Emotion Dysregulation in Eating Disorders and Obesity. https://doi.org/10.1093/oxfordhb/9780190653200.013.26
375. Sharma, S. (2021). Limited speech outside the home in a young girl who speaks normally at home. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197577479.003.0010
376. Sharma, S. (2021). Trouble being away from mother. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197577479.003.0012
377. Sharma, S., Kishore, J., & Gupta, V. (2014). Adolescent Mental Health: From Normalcy to Illness. Indian Journal of Youth and Adolescent Health.
378. Sharpe, M. (2010). Chronic fatigue syndrome (postviral fatigue syndrome, neurasthenia, and myalgic encephalomyelitis). Oxford University Press eBooks. https://doi.org/10.1093/med/9780199204854.003.260504
379. Shin, J.-S., & Sheen, Y.-I. (2006). A Research on the Epidermic disease of Abdominal Impulse etc. in SangHanMyungRiSokLon. Journal of Korean Medical classics.
380. Shprecher, D., & Mehta, L. (2010). The syndrome of delayed post-hypoxic  leukoencephalopathy.. PubMed.
381. Silva, L. I. F. D., Souza, L. M., Gonzales, M. F., & Jurado, S. R. (2015). SLEEP DISORDERS IN CHILDHOOD. Simpósio Internacional de Neurociências da Grande Dourados.
382. Silva, M., Santillana, R. D. H., Martı́n, M. Á., & Fiori, E. (2025). Post traumatic stress disorder in postpartum: when guilt delays recovery. A case report. European Psychiatry. https://doi.org/10.1192/j.eurpsy.2025.1949
383. Silverman, M. N., & Deuster, P. A. (2014). Biological mechanisms underlying the role of physical fitness in health and resilience. Interface Focus. https://doi.org/10.1098/rsfs.2014.0040
384. Singer, W., & Benarroch, E. E. (2014). Postural Tachycardia Syndrome. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199920198.003.0007
385. Siu-Fong, O. J., Ming-for, T. T., Lo, I. F. M., Chi-Wai, L., Ting-Yat, M., Trochet, D., & Tak-Sum, L. S. (2006). PHOX2B mutations in three Chinese patients with congenital central hypoventilation syndrome. Chinese Medical Journal. https://doi.org/10.1097/00029330-200610020-00014
386. Skraban, C., Grand, K., & Deardorff, M. A. (2019). WDR26-Related Intellectual Disability.
387. Slavić, A., & Manenica, I. (2005). Comparison in Heart Rate Variability during Working and Non-working Nights.
388. Smith, D. K., Sadler, K. P., & Benedum, M. (2019). Febrile Seizures: Risks, Evaluation, and Prognosis.. PubMed.
389. Smith, M., & Youngkin, E. Q. (1986). Managing the premenstrual syndrome. American Journal of Health-System Pharmacy. https://doi.org/10.1093/ajhp/43.11.2893
390. Smith, P. J., & Blumenthal, J. A. (2015). Exercise and Physical Activity in the Prevention and Treatment of Depression. Routledge eBooks. https://doi.org/10.4324/9780203132678.ch8
391. Smith, R. P. (2015). AGE, CULTURE, AND DIGITAL LITERACY: EXAMINING DIFFERENCES IN TRUST IN EHEALTH WEBSITES. The Gerontologist. https://doi.org/10.1093/geront/gnv367.02
392. Snyder, H. R., & Hankin, B. L. (2018). Working Memory and Youth depression. Routledge eBooks. https://doi.org/10.4324/9781315302072-13
393. Soares, P. S., Miranda, L. L., Monti, F. D. C., Zamboni, M. R., Santos, C. A., Cyrino, A. C. D. M., Takahashi, P. G., Pinheiro, J. B. D. P., Cerqueira, P. B. L., Bueno, C., Kok, F., Paz, J. A. D., Sampaio, L. P. B., Casella, E. B., Marques‐Dias, M. J., & Reed, U. C. (2014). Tetrahydrobiopterin (BH4) Deficiency: A Case Report. 13th International Child Neurology Congress (ICNC2014).
394. Solís, J. C. (2013). Diagnostico y tratamiento del síndrome premenstrual. Revista Médica de Costa Rica y Centroamérica.
395. Sommer, I. E., & Arango, C. (2017). Moving interventions from after to before diagnosis. World Psychiatry. https://doi.org/10.1002/wps.20454
396. Song, S. Y., Pei, Y., Tippett, S. R., Lamichhane, D., Zallek, C. M., & Hsiao‐Wecksler, E. T. (2018). Validation of a Wearable Position, Velocity, and Resistance Meter for Assessing Spasticity and Rigidity. 2017 Design of Medical Devices Conference. https://doi.org/10.1115/dmd2018-6906
397. Souza, C. D., Miranda, A. H., Venturin, M. D. D. D. L., & Marino, M. F. B. (2022). Bruxismo na psicanálise, quando a dor não se cala. AYA Editora eBooks. https://doi.org/10.47573/aya.5379.2.95.9
398. Soysal, P., & Işık, A. T. (2014). Hypoactive Delirium Caused by Pulmonary Embolus in an Elderly Adult. Journal of the American Geriatrics Society. https://doi.org/10.1111/jgs.12720
399. Spiegel, E. P., & Vanderploeg, R. D. (2010). Postconcussion Syndrome. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0696
400. Sriramoju, M., Keerthi, V. P., Alumdri, D. B., & Akula, S. (2014). Evaluation of antidepressant activity of ethanolic and aqueous extract of Solanum tuberosum peel. Journal of Comprehensive Pharmacy. https://doi.org/10.37483/jcp.2014.1503
401. Steiner, M., Pearlstein, T., Cohen, L. S., Endicott, J., Kornstein, S. G., Roberts, C. P., Roberts, D. L., & Yonkers, K. A. (2006). Expert Guidelines for the Treatment of Severe PMS, PMDD, and Comorbidities: The Role of SSRIs. Journal of Women s Health. https://doi.org/10.1089/jwh.2006.15.57
402. Stewart, S. M. (2013). Depression. The Encyclopedia of Cross‐Cultural Psychology. https://doi.org/10.1002/9781118339893.wbeccp158
403. Stifter, C. A. (2005). Crying Behaviour and its Impact on Psychosocial Child Development.
404. Stone, J., Carson, A., & Sharpe, M. (2005). Functional symptoms in neurology: management. Journal of Neurology Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp.2004.061663
405. Stone, J., Pal, S., Blackburn, D., Reuber, M., Thekkumpurath, P., & Carson, A. (2015). Functional (Psychogenic) Cognitive Disorders: A Perspective from the Neurology Clinic. Journal of Alzheimer s Disease. https://doi.org/10.3233/jad-150430
406. Strain, J. J., Klipstein, K., & Newcorn, J. H. (2008). Adjustment Disorders. Psychiatry. https://doi.org/10.1002/9780470515167.ch81
407. Strosahl, K. D. (2022). ACT con el paciente multiproblemático. ABA España eBooks. https://doi.org/10.26741/978-84-09-43990-4_09
408. Stubbe, D. (2007). Child and adolescent psychiatry : a practical guide. Lippincott Williams & Wilkins eBooks.
409. Subashini, S., Mathew, L., & Parmeshwar, P. (2021). A REVIEW ON PREMENSTRUAL SYNDROME. Journal of Emerging Technologies and Innovative Research.
410. Suchowersky, O., Reich, S. G., Perlmutter, J. S., Zesiewicz, T., Gronseth, G., & Weiner, W. J. (2006). Practice Parameter: Diagnosis and prognosis of new onset Parkinson disease (an evidence-based review) [RETIRED]. Neurology. https://doi.org/10.1212/01.wnl.0000215437.80053.d0
411. Syed, A. (2019). Migraine headache. International Journal of Biology Sciences. https://doi.org/10.33545/26649926.2019.v1.i2a.11
412. TAKANASHI, M. (2010). パーキンソン病の非運動症状. Juntendō Igaku/Juntendo igaku. https://doi.org/10.14789/pjmj.56.444
413. TAKEHARA, H., Matsukawa, Y., Tanaka, Y., Yamamoto, S., Horitani, R., & NISHIMORI, F. (2018). &lt;b&gt;Two Cases of Sleep Disorder with Developmental Disorders Successfully Treated with Kampo &lt;/b&gt;&lt;b&gt;Medicines&lt;/b&gt;. Kampo Medicine. https://doi.org/10.3937/kampomed.69.246
414. Taylor, H. G. (2010). Academic performance and learning disabilities. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511712166.017
415. Thakur, A., Choudhary, D., Kumar, B., & Chaudhary, A. (2021). A Review on Post-traumatic Stress Disorder (PTSD): Symptoms, Therapies and Recent Case Studies. Current Molecular Pharmacology. https://doi.org/10.2174/1874467214666210525160944
416. Thomas, P., Hazif‐Thomas, C., & Clément, J. (2008). [Loss of motivation in the elderly].. HAL (Le Centre pour la Communication Scientifique Directe).
417. Thomas, S., Zachariah, R. A., & Mathew, N. M. (2021). Perinatal Mental Health Problems –What Midwives and Nurses can do?. International Journal of Psychiatric Nursing. https://doi.org/10.37506/ijpn.v7i1.13967
418. Thompson, W., Longstreth, G. F., Drossman, D. A., Heaton, K. W., Irvine, E. J., & Müller‐Lissner, S. (1999). Functional bowel disorders and functional abdominal pain. Gut. https://doi.org/10.1136/gut.45.2008.ii43
419. Tolani, S. (2021). Impact of Major Depressive Disorder on Psychiatric Comorbidity of Females in Low Income Countries. Clinical and Experimental Psychology. https://doi.org/10.35248/2471-2701.21.7.244
420. Tom, N. R., Varghese, G. H., Lakshmi, S., & Sivakumar, T. (2014). Pre Menstrual Syndrome: Different Approaches of Management.
421. Tougas, G. (2000). The autonomic nervous system in functional bowel disorders. Gut. https://doi.org/10.1136/gut.47.suppl_4.iv78
422. Treanor, M., & Roemer, L. (2010). Generalized Anxiety Disorder. Corsini Encyclopedia of Psychology. https://doi.org/10.1002/9780470479216.corpsy0379
423. Tugendhaft, P. (2004). [The follow-up of antiepileptic drugs].. PubMed.
424. Ungvári, G. S., & Mullen, P. E. (2000). Reactive psychoses revisited. Australian & New Zealand Journal of Psychiatry. https://doi.org/10.1046/j.1440-1614.2000.00752.x
425. Unknown (1965). Drugs for the premenstrual syndrome. Drug and Therapeutics Bulletin. https://doi.org/10.1136/dtb.3.20.77
426. Utian, W. H. (2005). Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: A comprehensive review. Health and Quality of Life Outcomes. https://doi.org/10.1186/1477-7525-3-47
427. Valeriano, J., McConnell, H., & Brillman, J. C. (1995). Prenuptial seizures: a report of five cases. Journal of Neuropsychiatry. https://doi.org/10.1176/jnp.7.1.72
428. Valman, H. B. (1989). The first year of life. Convulsions in the older infant.. BMJ. https://doi.org/10.1136/bmj.299.6711.1331
429. Vernier, L., Peruch, C., Bartz, D., Barbosa, L. D. R., Cardoso, M. C. D. A. F., & Ramos, N. (2014). The Necessity of Speech-Language Intervention in West Syndrome Case: A Case Report. International Archives of Otorhinolaryngology. https://doi.org/10.1055/s-0034-1388969
430. Verrotti, A., Salladini, C., Trotta, D., Corcia, G. D., & Chiarelli, F. (2005). Ictal cardiorespiratory arrest in Panayiotopoulos syndrome. Neurology. https://doi.org/10.1212/01.wnl.0000162027.49577.1c
431. Vida, P. S., & Silva, L. A. M. (2019). Síndrome de Burnout em docentes. Psicologia e Saúde em Debate.
432. Viljoen, M. F. (2015). Sleep tips for insomnia patients. Mental Health Matters.
433. Vuppalapati, C., Kedari, S., Ilapakurti, A., Kedari, S., & Shankar, J. (2019). Emotional Health: A Data Driven Approach to Understand our Emotions and Improve our Health. https://doi.org/10.1109/cse/euc.2019.00071
434. Wakil, L., Meltzer‐Brody, S., & Girdler, S. S. (2012). Premenstrual Dysphoric Disorder: How to Alleviate Her Suffering; Accurate Diagnosis, Tailored Treatments Can Greatly Improve Women's Quality of Life. Current psychiatry.
435. Walterscheid, B., Eshak, N., & Nugent, K. (2021). Altered mental status in a patient with psychiatric history: Medication noncompliance or medical etiology?. Journal of Investigative Medicine.
436. Westgaard, R. H. (1996). Non-voluntary muscle activity and myofascial pain syndromes. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511570193.018
437. Wheeler, S. (2014). Approaches to Managing Executive Cognitive Functioning Impairment Following TBI: A Focus on Facilitating Community Participation. InTech eBooks. https://doi.org/10.5772/57395
438. Wijma, K., Wijma, B., & Cullhed, S. (1989). Learning-Theoretical Aspects of Primary Dysmenorrhea. Scandinavian Journal of Behaviour Therapy. https://doi.org/10.1080/16506078909456277
439. Wilson, D. S., & Nutt, P. D. J. (2013). Insomnia. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199674558.003.0003
440. Winters, K. C., & Ingwalson, A. (2022). Internalizing and Related Disorders. Oxford University Press eBooks. https://doi.org/10.1093/med-psych/9780190678487.003.0006
441. Wissow, L. S. (2021). Anxiety and Trauma-Related Distress. Pediatric Care Online. https://doi.org/10.1542/aap.ppcqr.396464
442. Wolf, J. M., & Paterson, S. (2010). Lifespan aspects of PDD/autism spectrum disorders (ASD). Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511674815.019
443. Wolters, F., Peerdeman, K. J., & Evers, A. W. (2019). Placebo and Nocebo Effects Across Symptoms: From Pain to Fatigue, Dyspnea, Nausea, and Itch. Frontiers in Psychiatry. https://doi.org/10.3389/fpsyt.2019.00470
444. Wrightson, P., & Gronwall, D. (1999). Clinical picture after mild head Injury. https://doi.org/10.1093/oso/9780192629395.003.0005
445. Wyatt, J. P., Illingworth, R. N., Graham, C. A., Hogg, K., Clancy, M., & Robertson, C. E. (2012). Environmental emergencies. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199589562.003.0006
446. Yamada, K. (2016). Effectiveness of ramelteon for residual sleep disturbances (hypersomnia) in a patient with premenstrual dysphoric disorder. Psychiatry and Clinical Neurosciences. https://doi.org/10.1111/pcn.12484
447. Yavuz, A. (2019). 2020 Market Analysis on Stress Management. Journal of Traumatic Stress Disorders & Treatment. https://doi.org/10.4172/2324-8947.1000e112
448. Yiu, M. G. C., Szeto, W., Wong, G., & Miao, M. (2009). Symptoms of Anxiety and Depression in the Perinatal Period: Referrals to the Comprehensive Child Development Service in a Hong Kong Regional Hospital. Hong Kong journal of psychiatry.
449. Yokoyama, H., Hirose, M., Nara, C., Wakusawa, K., Kubota, Y., Haginoya, K., Tsuchiya, S., & Iinuma, K. (2010). [A case of bipolar I disorder with autistic disorder showing "waiting-for-instruction" as a depressive symptom].. PubMed.
450. Yutzy, S. H. (2015). Somatic Symptom and Related Disorders: Somatic Symptom Disorder, Illness Anxiety Disorder, and Conversion Disorder. Psychiatry. https://doi.org/10.1002/9781118753378.ch62
451. Zawilska, J. B., & Tomaszewska, A. (2019). Psychoactive substances used to increase sexual activity: chemsex. Farmacja Polska. https://doi.org/10.32383/farmpol/116296
452. Zhao, N., Hu, W.-H., & Yuan, Z. (2011). [Analysis of symptom compositions in sub-health insomnia patients of Yin deficiency fire hyperactivity syndrome and Xin-Pi deficiency syndrome].. PubMed.
453. Zhiyan, S. (2014). PRELIMINARY SCREENING AND OPTIMIZATION OF ITEMS IN TRANDITIONAL CHINESE MEDICINE SYNDROME PRO SCALE IN DRUG ADDICTS. Zhongguo yaowu yilaixing zazhi.
454. Zoellner, L. A., Graham, B., & Bedard‐Gilligan, M. (2019). Trauma- and Stressor-Related Disorders. Routledge eBooks. https://doi.org/10.4324/9780429028267-10
455. Çelik, A. S., & Pasinlioğlu, T. (2013). KLİMAKTERİK DÖNEMDE YAŞANAN SEMPTOMLAR VE HEMŞİRENİN ROLÜ.
456. Žbulj, A. (2019). Psihičke poteškoće/poremećaji u razdoblju babinja.